Advertisement

Sonstige Psychopharmaka

  • W. E. Platz
  • J. Böning
  • W. Wesemann
  • N. Weiner
  • A. Hartmann
  • J. Deckert
  • C. H. Gleiter

Zusammenfassung

Clomethiazol ist chemisch ein Derivat des Thiazol-Anteils des Thiamins (Vitamin B1) mit
  • antikonvulsiven,

  • sedativen,

  • hypnotischen und auch

  • anxiolytischen

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Athen D (1986) Comparative investigation of chlormethiazole and neuroleptic agents in the treatment of alcoholic delirium. Acta Psychiatr Scand 329 (73): 167–170CrossRefGoogle Scholar
  2. Athen D, Hippids H, Meyendorf R, Riemer CH, Steiner CH (1977) Ein Vergleich der Wirksamkeit von Neuroleptika und Chlormethiazol bei der Behandlung des Alkoholdelirs. Nervenarzt 48: 528–532PubMedGoogle Scholar
  3. Bayer AJ, Bayer EM, Pathy MSJ, Stoker MJ (1986) A double-blind controlled study of chlormethia- zole and triazolam as hypnotics in the elderly. Acta Psychiatr Scand [Suppl 329] 73: 104–111CrossRefGoogle Scholar
  4. Beckmann H, Athen D (1978) Die Therapie des Delirium tremens. Dtsch Med Wochenschr 103: 1427–1428PubMedCrossRefGoogle Scholar
  5. Bekanntgabe Der Arzneimittelkommission Der DeutSchen Ärzteschaft (1977) Strenge Indikationsstellung für Clomethiazol. Dtsch Ärztebl 74: 1905Google Scholar
  6. Calverley PMA, Carmichael GLM, Scott DB (1984) The effect of chlormethiazole on the hypoxic drive to breathing in normal man. Br J Clin Pharmacol 18: 163–167PubMedCrossRefGoogle Scholar
  7. Calverley PMA, Carmichael GLM, Scott DB (1987) Die Behandlung des Delirium tremens bei Alkoholentzug. Arzneimittelbrief. Berlin, Jahrgang 21 (125): 97–100Google Scholar
  8. Douglas NJ, White DP, Weil JV et al. (1982) Hypoxic ventilatory response decrease during sleep in normal man. Am Rev Resp Dis 1235: 286–289Google Scholar
  9. Evans J, Lewis SA, Tinker M (1972) Chlormethiazole, sleep and drug withdrawal. Psychol Med 2: 239–247PubMedCrossRefGoogle Scholar
  10. Feuerlein W (1989) Aktuelle Beiträge zur Definition und Therapie der Alkoholkrankheit. Neuropsychiatrie 3: 7–12Google Scholar
  11. Fischer PA (1977) Intensivbehandlung des Alkoholentzugssyndroms. Diagnostik Intensivther 2: 9–11Google Scholar
  12. Geisler L, Herberg D (1967) Studies on the effect of some commonly used drugs on the excitability of the respiratory centre in man. Therapiewoche 47: 1941–1947Google Scholar
  13. Giacobini E, Salum I (1961) Treatment of delirium tremens. A comparative study of different therapeutic methods in 434 cases. Acta Psychiatr Scand 37: 198–208PubMedCrossRefGoogle Scholar
  14. Gsell S et al. (1972) Atem-und Herzstillstand unter Distraneurin. Nervenarzt 43: 635PubMedGoogle Scholar
  15. Helbig H (1962) Das tödliche Alkoholdelir. Nervenarzt 33: 221–226PubMedGoogle Scholar
  16. Hoensch HP (1986) Effect of chlormethiazole on the hepatic monooxygenase enzyme system. Acta Psychiatr Scand [Suppl 329] 73: 66–68CrossRefGoogle Scholar
  17. Holzbach E, Boiler KE (1978) Die Behandlung des Delirium tremens mit Haldol. Nervenarzt 49: 405–409PubMedGoogle Scholar
  18. Jostell KG (1987) Pharmacokinetics of chlormethiazole in man and influence of altered physiological conditions. Acta Univ Ups, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 31. Graphic Systems, StockholmGoogle Scholar
  19. Jostell KG et al. (1986) The bioavailability and pharmacodynamics of chlormethiazole in healthy young and elderly volunteers: praeliminary findings. Acta Psychiatr Scand [Suppl 329] 73: 32–33CrossRefGoogle Scholar
  20. Kalant H, Khanna JM (1986) Metabolic and functional aspects of tolerance to chlormethiazole and cross-tolerance to ethanol in the rat. Acta Psychiatr Scand [Suppl 329] 73: 45–53CrossRefGoogle Scholar
  21. Kalant H, Khanna JM, Llewellyn M, Rinkel GJE, Woodworth I (1986) Functional tolerance to chlormethiazole and crosstolerance to ethanol in the rat: importance of test and mode of drug administration. Acta Psychiatr Scand [Suppl 329] 73: 54–65CrossRefGoogle Scholar
  22. Keup W (1977) Das Abhängigkeitspotential des Clomethiazol (Distraneurin). Dtsch Arztebl 74: 1902–1905Google Scholar
  23. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkin-Son GR (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55: 347–359PubMedCrossRefGoogle Scholar
  24. Koo KW, Sax DS, Snider GL (1975) Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease. Am J Med 58: 663–670PubMedCrossRefGoogle Scholar
  25. Laborit H, Coirault R (1957) L’utilisation en clinique médicale et psychiatrique de l’action hypogéne d’un dérivé du noyau thiazolique de la Vitamine B1. Le S.C.T.Z. Sem Med (Paris) 33: 1704Google Scholar
  26. Laborit H, Coirault R, Damasio R, Guarjard R, Laborit G, Fabrizy P (1957) Sur un type nouveau d’anesthésie chirurgicale et sur e’emploi en thérapeutique d’un dépresseur du cortex cérébral. ( S.C.T.Z. ). Anesth Analg 14: 384Google Scholar
  27. Liljenberg B et al. (1986) The effects of chlormethiazole in EEG recorded sleep in normal elderly volunteers. Acta Psychiatr Scand [Suppl 329] 73: 34–39CrossRefGoogle Scholar
  28. Majumdar SK (1978) The effect of chlormethiazole on hepatic microsomal enzymes. Pharmatherapeutica 2: 27–30 (reprint)Google Scholar
  29. Majumdar SK (1981) Effects on the endocrine system of drugs used in treating the ethanol withdrawal syndrome: a survey. Drug Alcohol Depend 7: 379–385PubMedCrossRefGoogle Scholar
  30. Majumdar SK (1986) The influence of chlormethiazole on the neuroendocrine system in chronic alcoholics. Acta Psychiatr Scand [Suppl 329] 73: 69–72CrossRefGoogle Scholar
  31. Marion H, Schneider E (1970) Der Einfluß von Chlormethiazol ( Distraneurin) auf das SchlafElektroencephalogramm nach Alkoholdelir. Pharmakopsychiatr Neuro Psychopharm 3: 233–238Google Scholar
  32. Moore RG, Triggs EJ, Shanks CM, Thomas J (1975a) Pharmacokinetics of chlormethiazole in humans. Eur J Clin Pharmacol 8: 353–357PubMedCrossRefGoogle Scholar
  33. Moore RG, Robertson AV, Smytm I MP, Thomas J, Vine J (1975b) Metabolism and urinary excretion of chlormethiazole in humans. Xenobiotica 5: 687–696PubMedCrossRefGoogle Scholar
  34. Nies AS, Shand PG, Wilkinson GR (1976) Altered hepatic blood flow and drug disposition. Clin Pharmacokin 1: 135–155CrossRefGoogle Scholar
  35. Ogren SO (1986) Chlormethiazole-mode of action. Acta Psychiatr Scand [Suppl 329] 73: 13–27CrossRefGoogle Scholar
  36. Platz W (1981) Therapie medikamentös bedingter deliranter Syndrome, insbesondere bei Clomethiazol- Abhängigkeit. In: Keup W (Hrsg) Behandlung der Sucht und des Mißbrauchs chemischer Stoffe. 4. Wissenschaftliches Symposium der Deutschen Hauptstelle gegen die Suchtgefahren in Tutzing, 1980. Thieme, Stuttgart New York, S 65–73Google Scholar
  37. Platz W (1985) Medikamentöse Therapie bei gerontopsychiatrischen Notfällen. Med Klin 80: 511–513Google Scholar
  38. Pälsson A (1986) The efficacy of early chlormethiazole medication in the prevention of delirium tremens. A retrospective study of the outcome of different drug treatment strategies at the Helsingborg psychiatric clinics, 1975–1980. Acta Psychiatr Scand [Suppl 329] 73: 140–145CrossRefGoogle Scholar
  39. Schied HW, Mann K (1989) Die Behandlung des Delirium tremens und des Alkoholentzugssyndroms. In: Schied HW, Heimann H, Mayer K (Hrsg) Der chronische Alkoholismus. Fischer, Stuttgart New York, S 285–300Google Scholar
  40. Schmehling E (1967) Atemdepression nach Distraneurin? Nervenarzt 38: 266–269PubMedGoogle Scholar
  41. Schmidt L (1986) Alkoholkrankheit Alkoholmißbrauch. Kohlhammer, Stuttgart Berlin Köln MainzGoogle Scholar
  42. Scott DB (1986) Circulatory and respiratory effects of chlormethiazole. Acta Psychiatr Scand [Suppl 329] 73: 28–31CrossRefGoogle Scholar
  43. Stille G (1986) Das Abhängigkeitspotential von Clomethiazol. In: Evans G, Feuerlein W, Glatt MM, Kanowski S, Scott DB (Hrsg) Clomethiazol. Verlag für angewandte Wissenschaften, München, S 103–109Google Scholar
  44. Who Expert Committee on Drug Dependence (1988) Twenty-fourth report. Technical Report Series 761. World Health Organization, Geneva, pp 11–13Google Scholar
  45. Ahrens R (1991) Androcur (Cyproteronacetat) bei Sexualdelinquenz — Nachuntersuchung von untergebrachten psychiatrischen Patienten. Schweiz Arch Neurol Psychiatr 142: 171–188PubMedGoogle Scholar
  46. Bancroft J, Tennent G, Loucas K, Cass J (1974) The control of deviant sexual behaviour by drugs. Br J Psychiatry 125: 310–315PubMedCrossRefGoogle Scholar
  47. Bhargava AS, Soeger A, Günzel P (1977) Isolation und identification of 15-beta-hydroxy cyproterone acetats as a new metabolite of cyproterone acetate in dog, monkey and man. Steroids 30: 407PubMedCrossRefGoogle Scholar
  48. Binder S, Roters G, Schultka H (1971) Klinische und experimentell-psychologische Untersuchungen zur Wirkung des Antiandrogens Cyproteronazetat bei erheblich vermindert zurechnungsfähigen und zurechnungsunfähigen Sexualdelinquenten. Nervenarzt 42: 26PubMedGoogle Scholar
  49. Cooper AJ, Ismail AAA, Phanjoo AL, Lone DL (1972) Anti-androgen therapy in deviant hypersexuality. Br J Psychiatry 102: 59CrossRefGoogle Scholar
  50. Dorfmann RI (1970) Serum assays and anti-androgens. Biological activity on antiandrogens. Br J Dermatol 82 [Suppl 61: 3–8CrossRefGoogle Scholar
  51. Fähndrich E (1974) Cyproteronacetat in der Behandlung von Sexualdeviationen bei Männern. Dtsch Med Wochenschr 99: 234PubMedCrossRefGoogle Scholar
  52. Herrmann WM, Beach RC (1978) Experimental and clinical data indicating the psychotropic properties of progestogens. Postgraduate Med J 54 [Suppl 2]: 82–87Google Scholar
  53. Hoffet H (1968) Die medizinischen Behandlungsmöglichkeiten von Sexualdelinquenten. Schweiz Z Strafrecht 84: 377Google Scholar
  54. Hoffet H (1969) Neue Wege in der Behandlung von Sexualdelinquenten. Kriminalistik 23: 405Google Scholar
  55. Hoffet H (1980) Die klinische Anwendung von Antiandrogenen in der Psychiatrie. Gynäkologe 13: 33–43PubMedGoogle Scholar
  56. Horn HJ (1971) Der Leidensdruck als Indikationskriterium. Bemerkungen zur “medikamentösen Kastration”. Nervenarzt 42: 312PubMedGoogle Scholar
  57. Itil TM, Cora R, Akpinar S, Herrmann WM, Patter-Son CI (1974) Psychotropic action of sex hormones. Curr Ther Res 16. 11: 1147Google Scholar
  58. Kockott G (1983) Die Behandlung sexueller Delinquenz mit Antiandrogenen. Psychiat Prax 10: 158–164Google Scholar
  59. Laschet U (1970) Ergebnisse neuer medikamentöser Behandlungsmethoden bei Sexualdelinquenten. Kriminolog Gegenwartsfragen 9: 174–179Google Scholar
  60. Laschet U (1988) Die Behandlung männlicher Sexualdeviationen. 20 Jahre Erfahrungen mit Androcur. Vorlesungsreihe Schering, Heft 20Google Scholar
  61. Laschet U, Laschet L (1971) Psychopharmacotherapy of sex offenders with cyproterone acetate. Pharmakopsychiatr Neuro Psychopharmakol 4: 99–104CrossRefGoogle Scholar
  62. Laschet U, Laschet L (1978) Ten years cyproterone acetate for the modification of sexual behaviour in men. bga-Berichte 3: 91–96Google Scholar
  63. Menghini P, Ernst K (1991) Die Antiandrogenbehandlung im rückblickenden Urteil von 19 Sexualstraftätern. Nervenarzt 62: 303–307PubMedGoogle Scholar
  64. Micheroli R, Battegay R (1985) Ambulante Behandlung von Sexualdelinquenten mit Cyproteronacetat ( Androcur ). Schweiz Arch Neurol Neurochir Psychiatr 136: 37–58Google Scholar
  65. Mothes C, Lehnert J, Samimi F, Ufer J (1973) Klinische Prüfung von Cyproteronacetat ( Androcur) bei Sexualdeviationen - Gesamtauswertung. Med Mitteilungen 2: 26–39Google Scholar
  66. Neumann F (1977) Normale und gestörte Sexualdifferenzierung. Medizin in unserer Zeit 1: 98–108Google Scholar
  67. Neumann F (1978) Chemie, Biochemie und pharmakologische Grundlagen der Antiandrogene. Dtsch Ärztebl 75: 1633–1640Google Scholar
  68. Neumann F (1986) Pharmacology and clinical uses of cyproteron-acetate. In: Furr BJA, Wakeling AE (eds) Pharmacology and clinical uses of inhibitors of hormone secretion and action. Bailliére Tindall, London Philadelphia Toronto Mexico City Sydney Tokyo Hong Kong, pp 132–159Google Scholar
  69. Neumann F (1989) Möglichkeiten der pharmakodynamischen Beeinflussung des Sexualverhaltens. Symposium Sexualmedizin, HeidelbergGoogle Scholar
  70. Neumann F, Elger W (1966) Permanent changes in gonadal function and sexual behaviour as a result of early feminization of male rats by treatment with an antiandrogenic steroid. Endokrinologie 50: 209–225PubMedGoogle Scholar
  71. Neumann F, Wiechert R (1984) Die Geschichte von Cyproteronacetat. MPS, Med Pharmazeut Studienges e.V., Mainz. Berichte aus der PharmaForschung, Bd I IIGoogle Scholar
  72. Neumann F, Wiechert R (1988) Das Antiandrogen Cyproteron-acetat. Pharmazie in unserer Zeit 17: 33–50PubMedCrossRefGoogle Scholar
  73. Neumann F, Elger W, Steinbeck H (1970) Antiandrogens and reproductive development. Phil Trans Roy Soc Lond B 259: 179–184CrossRefGoogle Scholar
  74. Neumann F, Schleusener A, Albring M (1978) Pharmacology of antiandrogens. IN: Hammerstein J, Lachnit-Fixson U, Neumann F, Plewig G (eds) Androgenization in women–acne, seborrhoea, androgenetic alopecia and hirsutism. Excerpta Medica, Amsterdam Oxford Princeton, pp 147–192Google Scholar
  75. Neumann F, Schleusener A, Humpel M (1979) Antiandrogene. Gynäkologe 12: 228–242Google Scholar
  76. Ott F, Hoffet H (1968) Beeinflussung von Libido, Potenz und Hodenfunktion durch Antiandrogene. Schweiz Med Wochenschr 98: 1812–1815Google Scholar
  77. Rasch W (1978) Sexuelle Devianz und strafrechtliche Sanktion. In: Füllgraff G, Barbey I (Hrsg) Abschlußbericht der Kommission beim Bundesgesundheitsamt: Stereotaktische Hirnoperationen bei abweichendem Sexualverhalten (bga-Berichte 3 ). D Reimer, Berlin, S 111–114Google Scholar
  78. Rasch W (1986) Forensische Psychiatrie. Kohlhammer, Stuttgart Berlin Köln MainzGoogle Scholar
  79. Raspé G (ed) (1972) Schering Symposium über Sexualdeviationen und ihre medikamentöse Behandlung. Life Science Monographs 2. Pergamon Press. Vieweg, Oxford Edinburgh New York Toronto Sydney BraunschweigGoogle Scholar
  80. Schacher A, el Etreby MF, Neumann F (1984) Einfluß von Cyproteronacetat, Flutamid und Spironolacton auf die Achse Hypothalamus-Hypophyse-Hoden bei Ratten. Akt Urol 15: 218Google Scholar
  81. Sigusch V (1979) Die Behandlung mit Antiandrogenen. Sexualmedizin 8: 13–19Google Scholar
  82. Wiechert R, Neumann F (1965) Gestagene Wirksamkeit von 1-Methyl-und 1,2a-Methylen-Steroiden. Arzneimittelforschung 15: 244–246Google Scholar
  83. Azrin NH, Sisson RW, Meyer SR, Godley M (1982) Alcoholism treatment by disulfiram and com- munity reinforcement therapy. J Behav Ther Exp Psychiatry 13: 105–112PubMedCrossRefGoogle Scholar
  84. Bartmann U, Fautsch J (1991) Eine Chance für die ambulante Therapie. Psycho 17: 192–202Google Scholar
  85. Bartonicek V, Teisinger J (1962) Effect of tetraethyl thiuram disulphide (disulfiram) on metabolism of trichloro-ethylene in man. Br J Industr Med 19: 216–221Google Scholar
  86. Bilbao JM, Briggs SJ, Gray TA (1984) Filamentous axonopathy in disulfiram neuropathy. Ultrastruct Pathol 7: 295–300PubMedCrossRefGoogle Scholar
  87. Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, Ritson B, Ropner R, Torley D (1992) Disulfiram treatment of alcoholism. Br J Psychiatry 161: 84–89PubMedCrossRefGoogle Scholar
  88. Christensen JK, Ronsted P, Vaag VH (1984) Side effects after disulfiram. Acta Psychiatr Scand 69: 265–273PubMedCrossRefGoogle Scholar
  89. Ciraulo DA, Barnhill J, Boxenbaum H (1985) Pharmacokinetic interaction of disulfiram and an- tidepressants. Am J Psychiatry 142: 1373–1374PubMedGoogle Scholar
  90. Coger RW, Dymond AM, Serafetinides EA et al. (1976) Averaged visual evoked response amplitude-intensity slope and symmetry in withdrawal. Biol Psychiatry 11: 435–443PubMedGoogle Scholar
  91. Cushmann P (1986) Sedative drug interactions of clinical importance. In: Galanter M (ed) Alcoholism, vol 4. Plenum Press, New York LondonGoogle Scholar
  92. Feuerlein W (1989) Alkoholismus — Mißbrauch und Abhängigkeit, 4. Aufl. G Thieme, StuttgartGoogle Scholar
  93. Fischer I (1945) Säregen svampförgiftining. Sv Läk-Tidn 42: 2513–2515Google Scholar
  94. Fuller RK (1988) Disulfiram treatment of alcoholism. In: ROSE RM, BARRET JE (eds) Alcoholism: origins and outcome. Raven Press, New York, pp 237–244Google Scholar
  95. Fuller RK, Roth HP (1979) Disulfiram for the treatment of alcoholism: an evaluation in 128 men. Ann Intern Med 90: 901–904PubMedGoogle Scholar
  96. Fuller RK, Williford WO (1980) Life-table analysis of abstinence in a study evaluating the efficacy of disulfiram. Alcohol Clin Exp Res 4: 298–301PubMedCrossRefGoogle Scholar
  97. Gill K, Amit Z (1989) Serotonin uptake blockers and voluntary alcohol consumption. A review of recent studies. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 225–248Google Scholar
  98. Halo E, Jacobson I (1948) A drug sensitising the organism to ethylalcohol. Lancet 11: 1001–1003Google Scholar
  99. Haubroe K (1980) What we know today about “Antabuse® (Disulfiram)”. Manedsskrift for praktisk Laegegerning 58: 30–40Google Scholar
  100. Iber FL, Lee K, Lacoursiere R, Fuller R (1987) Liver toxicity encoutered in the Veterans Administration trial of disulfiram in alcoholics. Alcohol Clin Res 11: 301–304CrossRefGoogle Scholar
  101. Jacobsen E (1967a) Neues über die theoretische Grundlage der Disulfiram-Wirkung. Med Welt 18 (N.F.): 2169–2173Google Scholar
  102. Jacobsen E (1967b) Die Verwendung von Disulfiram (Antabus®). Med Welt 18 (N.F.): 2230–2234Google Scholar
  103. Jaffe JH, Ciraulo DA (1985) Drugs used in the treatment of alcoholism. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd ed. McGraw-Hill, New YorkGoogle Scholar
  104. Jensen E (1984) A proper use of Antabuse, the Danish model of treatment. Br J Clin Pract [Suppl 36] 38: 2–4Google Scholar
  105. Kitson TM (1977) The disulfiram-ethanol reaction. J Studies Alcohol 38: 96–113Google Scholar
  106. Koelsch F (1914) Über neuartige gewerbliche Erkrankungen in Kalkstickstoffbetrieben. Münch Med Wochenschr 35: 1869–1870Google Scholar
  107. Koivusalo M (1956) Studies on the metabolism of methanol and formaldehyde in the animal organism. Acta Physiol Scand 39 [Suppl 131]Google Scholar
  108. Küfner H, Feuerlein W (1989) In-patient treatment for alcoholism. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  109. Lenz H (1957) Zur Ursache der fehlenden Antabus-Alkohol-Reaktion. Wien Klin Wochenschr 38 /39: 743Google Scholar
  110. Lindros KO, Stowell A, Pikkarainen P, Salaspuro M (1981) The disulfiram (Antabuse) alcohol reaction in male alcoholics: its efficient management by 4-methylpyrazole. Alcohol Clin Exp Res 5: 528–530PubMedCrossRefGoogle Scholar
  111. Macleod SM, Sellers EM, Giles HG, Billings BJ, Martin PR, Greenblatt DJ, Marshman JA (1978) Interaction of disulfiram with benzodiazepines. Clin Pharmacol Ther 24: 583–589PubMedGoogle Scholar
  112. Mccrady B (1989) Outcomes of family-involved alcoholism treatment. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 165–182Google Scholar
  113. Nutt D, Adinoff B, Limoila M (1989) Benzodiazepines in the treatment of alcoholism. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 283–313Google Scholar
  114. Pattison EM (1985) The selection of treatment modalities for the alcoholic patient. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd ed. McGraw-Hill, New YorkGoogle Scholar
  115. Peeke SC, Prael AR, Herning RI et al. (1979) Effect of disulfiram on cognition, subjective response, and cortical event-related alcoholic in nonalcoholic subjects. Alcohol Clin Exp Res 3: 223–229PubMedCrossRefGoogle Scholar
  116. Perman ES (1962) Effect of ethanol on oxygen uptake and on blood glucose concentration in anesthetized rabbits. Acta Physiol Scand 55: 189–202PubMedCrossRefGoogle Scholar
  117. Platz WE (1992) Alkoholkriminalität (in Vorbereitung)Google Scholar
  118. Rainey JM (1977) Disulfiram toxicity and carbon disulfide poisoning. Am J Psychiatry 134: 371–378PubMedGoogle Scholar
  119. Robichaud C, Strickler D, Bigelow G, Liebson I (1979) Disulfiram maintenance employee alcoholism treatment: a three-phase evaluation. Behav Ther 14: 618–621Google Scholar
  120. Schmidt L (1986) Alkoholkrankheit and Alkoholmißbrauch. Kohlhammer, StuttgartGoogle Scholar
  121. Schuckit MA (1981) Disulfiram (Antabuse) and the treatment of alcoholic men. Adv Alcohol 11: 1–4Google Scholar
  122. Schuckit MA (1985a) Treatment of alcoholism in offices and outpatient settings. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd ed. McGraw-Hill, New YorkGoogle Scholar
  123. Schuckit MA (1985b) A one-year follow-up of men alcoholics given disulfiram. J Stud Alcohol 46: 191–195PubMedGoogle Scholar
  124. Schuckit MA ( 1985 c) Inpatient and residential approaches to the treatment of alcoholism. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd ed. McGraw-Hill, New YorkGoogle Scholar
  125. Schuckit MA (1989) Drug and alcohol abuse. Plenum, New York LondonGoogle Scholar
  126. Sellers EM, Naranjo CA, Peachey JE (1981) Drugs to decrease alcohol consumtion. N Engl J Med 305: 1255–1262PubMedCrossRefGoogle Scholar
  127. Staub H (1955) Beiträge zum Antabuse-Problem. Helv Physiol Acta 13: 121–140Google Scholar
  128. Strömme JH, Eldjarn L (1966) Distribution and chemical forms of diethyldithiocarbamate and tetraethylthiuram disulphide ( Disulfiram) in mice in relation to radioprotection. Biochem Pharmacol 15: 287–297Google Scholar
  129. Truitt EB, Duritz G, Morgan AM, Prouty RW (1962) Disulfiram-like actions produced by hypoglycemic sulfonylurea compounds. Q J Stud Alcohol 23: 197–207PubMedGoogle Scholar
  130. Usdin GL, Rond PC, Hinchcliffe JA, Ross WD (1952) The meaning of disulfiram to alcoholics in group psychotherapy. Q J Stud Alcohol 13: 590–599PubMedGoogle Scholar
  131. Williams EE (1937) Effects of alcohol on workers with carbon disulfide. JAMA 109: 1472–1473CrossRefGoogle Scholar
  132. Apter A, Van Praag HM, Plutchik R, Sevy S, Korn M, Brown SL (1990) Interrelationships among anxiety, aggression, impulsivity, and mood: a serotonergically linked cluster? Psychiatry Res 32: 191–199PubMedCrossRefGoogle Scholar
  133. Ball JC, Ross A (1991) (eds) The effectiveness of methadone maintenance treatment. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  134. Balldin JK, Berggren UC, Lindstedt G (1992) Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. Alcoholism Clin Exp Res 16: 71–74CrossRefGoogle Scholar
  135. Barnes DM (1988) The biological triangle of drug addiction. Science 241: 415–417PubMedCrossRefGoogle Scholar
  136. Baumgarten HG (1991) Neuroanatomie und Neurophysiologie des zentralen 5-HT-Systems. In: Heinrich K, Hippius H, Poldinger W (Hrsg) Serotonin–ein funktioneller Ansatz für die psychiatrische Diagnose und Therapie? Springer, Berlin Heidelberg New York Tokyo, S 17–44Google Scholar
  137. Bergmark A, Oscarsson L (1987) The concept of control and alcoholism. Br J Addict 82: 1203–1212PubMedCrossRefGoogle Scholar
  138. Bloom FE (1987) Future directions and goals in basic psychopharmacology. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 1685–1689Google Scholar
  139. Blum K, Briggs AH, Trachtenberg M (1989) Ethanol ingestive behaviour as a function of central neurotransmission. Experientia 45: 444–452PubMedCrossRefGoogle Scholar
  140. Boning J (1989) Anxiety and dependence–reason or consequence? Psychiat Fen [Suppl] 20: 83–90Google Scholar
  141. Boning J (1991) Zur Neurobiologie und Psychopathologie süchtigen Verhaltens. In: Wanke K, Behringer G (Hrsg) Grundstörungen der Sucht.Springer, Berlin Heidelberg New York Tokyo, S 1–27Google Scholar
  142. Brahen LS, Capone TJ, Capone DM (1988) Naltrexon: lack of effect on liver enzymes. J Clin Pharmacol 28: 64–70PubMedGoogle Scholar
  143. Breese GR, Criswell HE, Mueller RA (1990) Evidence that lack of brain dopamine during development can increase the susceptibility for aggression and self-injurious behaviour by influencing D1-dopamine receptor function. Prog Neuro Psychopharmacol Biol Psychiatry 14: S 65–80CrossRefGoogle Scholar
  144. Brewer C, Rezae H, Bailey C (1988) Opioid withdrawal and naltrexone induction in 48–72 hours with minimal dropout, using a modification of the naltrexone-clonidine technique. Br J Psychiatry 153: 340–343PubMedCrossRefGoogle Scholar
  145. Bronisch F (1990) Alcoholism and depression. Prog Alcohol Res 2: 69–99Google Scholar
  146. Bruno F (1989) Buspirone in the treatment of alcoholic patients. Psychopathology 22: 49–59PubMedCrossRefGoogle Scholar
  147. Buydens-Branchey L, Branchey MH, Noumair D (1989) Age of alcoholism onset. I. Relationship to psychopathology. II. Relationship to susceptibility to serotonin precursor availability. Arch Gen Psychiatry 46: 225–230, 231–236Google Scholar
  148. Cadoret RJ, Troughton E, Bagford J, Woodworth G (1990) Genetic and environmental factors in adoptee antisocial personality. Eur Arch Psychiatr Neurol Sci 239: 231–240CrossRefGoogle Scholar
  149. Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236: 410–416PubMedCrossRefGoogle Scholar
  150. Cloninger CR, Sigvardsson S, Bohman M (1988) Childhood personality predicts alcohol abuse in young adults. Alcoholism Clin Exp Res 12: 494–505CrossRefGoogle Scholar
  151. Collingridge GL, Davies SN (1989) NMDA receptors and long-term potentiation in the hippocampus. In: Watkins JC, Collingridge GL (eds) The Nmda receptor. IRL Press, Oxford, pp 123–136Google Scholar
  152. Costall B, Jones BJ, Kelly ME, Naylor RJ, Onaivi ES, Tyres MB (1990) Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 36: 339–344PubMedCrossRefGoogle Scholar
  153. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. PNAS 85: 5274–5278PubMedCrossRefGoogle Scholar
  154. Dongier M, Vachon L, Schwartz G (1991) Bromocriptine in the treatment of alcohol dependence. Alcoholism Clin Exp Res 15: 970–977CrossRefGoogle Scholar
  155. Dorus W, Ostrow DG, Anton R et al. (1989) Lithium therapy of depressed and nondepressed alcoholics. JAMA 262: 1646–1652PubMedCrossRefGoogle Scholar
  156. Fawcett J, Clark DC, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, Mcguire M, Gibbons RD (1987) A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry 44: 248–256PubMedCrossRefGoogle Scholar
  157. Finlay JM, Damsma G, Fibiger HC (1992) Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration. Psychopharmacology 106: 202–208PubMedCrossRefGoogle Scholar
  158. Friessem DH, Täschner KL (1991) Codein and Dihydrocodein als Ausweich-and Ersatzdrogen. Fortschr Neurol Psychiat 59: 164–169PubMedCrossRefGoogle Scholar
  159. Garcia-Alonso F, Gutierrez M, San L et al. (1989) A multicenter study to introduce naltrexone for opiate dependence in Spain. Drug Alcohol Depend 23: 117–121PubMedCrossRefGoogle Scholar
  160. Gawin FH, Kleber HD (1984) Cocaine abuse treatment: open pilot trial with desipramine and lithium carbonate. Arch Gen Psychiatry 42: 903–910CrossRefGoogle Scholar
  161. Gawin FH, Allen D, Humblestone B (1989) Outpatient treatment of “crack” cocaine smoking flupentixol decanoate a preliminary report. Arch Gen Psychiatry 46: 322–325PubMedCrossRefGoogle Scholar
  162. George DT, Adinoff B, Ravitz B, Nutt DJ, Dejong J, Berrettini W, Mefford IN, Costa E, Linnoila M (1990a) A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism. Acta Psychiatr Scand 82: 1–7PubMedCrossRefGoogle Scholar
  163. George DT, Nun DJ, Dwyer BA, Linnoila M (1990b) Alcoholism and panic disorder: is the comorbidity more than coincidence? Acta Psychiatr Scand 81: 97–107PubMedCrossRefGoogle Scholar
  164. Ginzburg HM (1986) Naltrexone: its clinical utility. Adv Alcohol Subst Abuse 5: 83–101CrossRefGoogle Scholar
  165. Goldstein A (1989) (ed) Molecular and cellular aspects of the drug addictions. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  166. Graeff FL (1986) 5-Hydroxytryptamine, aversion, and anxiety. Behav Brain Sci 9: 339–340Google Scholar
  167. Gronbladh L, Ohlund LS, Gunne LM (1990) Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 82: 223–227PubMedCrossRefGoogle Scholar
  168. Hartmann F, Poirier MF, Bourdel MC, Loo H, Le-Comte JM, Schwartz JC (1991) Comparison of acetorphan with clonidine for opiate withdrawal symptoms. Am J Psychiatry 148: 627–629PubMedGoogle Scholar
  169. Havemann-Reinecke U (1991) Sucht–zur neuro-biologischen Grundlagenforschung in der Bundesrepublik. In: Materialien zur Gesundheitsforschung. Schriftreihe zum Programm der Bundesregierung Forschung und Entwicklung im Dienste der Gesundheit (Hrsg) Suchtforschung: Bestandsaufnahme und Analyse des Forschungsbedarfs. Bonn (Bd 19 ), S 33–49Google Scholar
  170. Hawkes CH (1992) Endorphins: the basis of pleasure? J Neurol Neurosurg Psychiatry 55: 247–250PubMedCrossRefGoogle Scholar
  171. Herz A, Shippenberg TS (1989) Neurochemical aspects of addiction: opioids and other drugs of abuse. In: Goldstein A (ed) Molecular and cellular aspects of the drug addiction. Springer, Berlin Heidelberg New York Tokyo, pp 111–142CrossRefGoogle Scholar
  172. Hubbard RL, Rachal JV, Craddock SG, Cavanaugh ER (1984) Treatment outcome prospective study (TOPS): client characteristics and behaviours before, during, and after treatment. In: TIMs FM, Ludford JP (eds) Drug abuse treatment evaluation: strategies, progress and prospects. NIDA, Rockville, MD, pp 42–68 (Monograph series 51 )Google Scholar
  173. Hutson PH, Bristow LJ, Thorn L, Tricklebank MD (1991) R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br J Pharmacol 103: 2037–2044PubMedCrossRefGoogle Scholar
  174. Irwin M, Schuckit M, Smith TL (1990) Clinical importance of age at onset in type 1 and type 2 primary alcoholics. Arch Gen Psychiatry 47: 320–324PubMedCrossRefGoogle Scholar
  175. Johnston AL, Thevos AK, Randall CL, Anton RF (1991) Increased severity of alcohol withdrawal in in-patient alcoholics with a co-existing anxiety diagnosis. Br J Addict 86: 719–725PubMedCrossRefGoogle Scholar
  176. Kahn RS, Wetzler S (1991) m-chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30: 1139–1166Google Scholar
  177. Kalant H (1989) The nature of addiction: an analysis of the problem. In: Goldstein A (ed) Molecular and cellular aspects of the drug addictions. Springer, Berlin Heidelberg New York Tokyo, pp 1–28CrossRefGoogle Scholar
  178. Keup W (1990) Eignung für Methadon-Erhaltungs-programme in einer Zufallsstichprobe von Drogenabhängigen. Suchtgefahren 36: 243–249Google Scholar
  179. Keup W (1991) Naltrexon–Einsatz für Opiatab- hängige. Arzneimitteltherapie 5: 129–132Google Scholar
  180. Knorring AL V, Bohman M, Knorring L V, Oreland L (1985) Platelet MAO activity as a biological marker in subgroups of alcoholism. Acta Psychiatr Scand 72: 51–58CrossRefGoogle Scholar
  181. Knorring AL V, Hallman J, Knorring L v, Oreland L (1991) Platelet monoamine oxidase activity in type I and type 2 alcoholism. Alcohol Alcoholism 26: 409–416Google Scholar
  182. Knorring L V, Knorring AL v, Smigan L, Lindberg Y, Edholm M (1987) Personality traits in subtypes of alcoholics. J Stud Alcohol 48: 523–527Google Scholar
  183. Kosten TA, Kosten TR (1991) Pharmacological blocking agents for treating substance abuse. J Nerv Ment Dis 179: 583–592PubMedCrossRefGoogle Scholar
  184. Kosten TR, Kleber HD, Morgan C (1989) Role of opioid antagonists in treating intravenous cocain abuse. Life Sci 44: 887–892PubMedCrossRefGoogle Scholar
  185. Kosten TR, Morgan C, Kleber HD (1991) Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 17: 119–128PubMedCrossRefGoogle Scholar
  186. Kryspin-Exner K (1983) Psychopharmakotherpie bei Abhängigkeitsprozessen von Alkohol, Medikamenten und Drogen. In: Langer G, Hei-Mann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York, S 491–514Google Scholar
  187. Krystal JH, Leaf PJ, Bruce ML, Charney DS (1992) Effects of age and alcoholism on the prevalence of panic disorder. Acta Psychiatr Scand 85: 77–82PubMedCrossRefGoogle Scholar
  188. Kuschinsky K (1981) Psychic dependence on opioids: mediated by dopaminergic mechanisms in the striatum? TINS 11: 287–289Google Scholar
  189. Kushner MG, Kenneth MA, Sher J, Beitman BD (1990) The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 147: 685–695PubMedGoogle Scholar
  190. Lee MA, Meltzer HY (1991) Neuroendocrine responses to serotonergic agents in alcoholics. Biol Psychiatry 30: 1017–1030PubMedCrossRefGoogle Scholar
  191. Lesch OM, Walter H, Bonte W, Grunberger J, Mu-Salek M, Sprung R (1991) Etiology of subgroups in chronic alcoholism and different mechanisms in transmitter systems. In: Palmer TN (ed) Alcoholism–a molecular perspective. Nato, Life Sciences 206: 137–152Google Scholar
  192. Limson R, Goldman D, Roy A, Lamparski D, Ravitz B, Adinoff B, Linnoila M (1991) Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls. Arch Gen Psychiatry 48: 437–441PubMedCrossRefGoogle Scholar
  193. Linnoila M, Eckardt M, Durcan M, Lister R, Martin P (1987) Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull 23: 452–457PubMedGoogle Scholar
  194. Liskow BI, Goodwin DW (1987) Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review. J Stud Alcohol 48: 356–370PubMedGoogle Scholar
  195. Loimer N, Lenz K, Schmid R, Presslich O (1991) Technique for greatly shortening the transition form methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry 148: 933–935PubMedGoogle Scholar
  196. Malka R, Loo H, Ganry H, Souche A, Marey C, Kamoun A (1992) Long-term administration of tianeptine in depressed patients after alcohol withdrawal. Br J Psychiatry 160: 66–71Google Scholar
  197. Mason BJ, Kocsis JH (1991) Desipramine treatment of alcoholism. Psychopharmacol Bull 27: 155–161PubMedGoogle Scholar
  198. Meert TF, Janssen PAJ (1991) Ritanserin, a new therapeutic approach for drug abuse. Part 1. Effects on alcohol. Drug Dev Res 24: 235–249Google Scholar
  199. Meert TF, Janssen PAJ (1992a) Ritanserin, a new therapeutic approach for drug abuse. Part 2. Effects on cocaine. Drug Dev Res 25: 39–53Google Scholar
  200. Meert TF, Janssen PAJ (1992b) Ritanserin, a new therapeutic approach for drug abuse. Part 3. Effects on fentanyl and sucrose. Drug Dev Res 25: 55–66Google Scholar
  201. Meyer RE (1989) Prospects for a rational pharmacotherapy of alcoholism. J Clin Psychiatry 50: 403–412PubMedGoogle Scholar
  202. Meyers R, Beil H (1989) Ambulante Behandlung von Alkohol-and Drogenabhängigen. Munch Med Wochenschr 131: 489–493Google Scholar
  203. Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263–287PubMedCrossRefGoogle Scholar
  204. Miller FT, Busch F, Hertz-Tanenbaum J (1989) Drug abuse in schizophrenia and bipolar disorder. Am J Drug Alcohol Abuse 15: 291–295PubMedCrossRefGoogle Scholar
  205. Miller NS, Ries RK (1991) Drug and alcohol dependence and psychiatric populations: the need for diagnosis, intervention and training. Compr Psychiatry 32: 268–276PubMedCrossRefGoogle Scholar
  206. Möller HG, Nowak K, Kuschinsky K (1987) Conditioning of pre-and postsynaptic behavioural responses to the dopamine receptor agonist apomorphine in rats. Psychopharmacology 91: 50–55PubMedCrossRefGoogle Scholar
  207. Moody CA, Spear LP (1992) Ontogenetic differences in the psychopharmacological responses to separate and combined stimulation of D, and D2 dopamine receptors during the neonatal to weanling age period. Psychopharmacology 106: 161–168PubMedCrossRefGoogle Scholar
  208. Morris RGM, Davis S, Butcher SP (1989) The role of NMDA receptors In learning and memory. In: Watkins JC, Collingridge GL (eds) The NMDA receptor. IRL Press, Oxford New York Tokyo, pp 137–152Google Scholar
  209. Myers RD (1989) Isoquinolines, (3-carbolines and alcohol drinking: involvement of opioid and dopaminergic mechanisms. Experientia 45: 436–443PubMedCrossRefGoogle Scholar
  210. Nace EP, Davis GW, Gaspari JP (1991) Axis II comorbidity in substance abusers. Am J Psychiatry 148: 118–120PubMedGoogle Scholar
  211. Noble EP, Blum K, Ritchie T, Montgomery A, Sheri-Dan PJ (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48: 648–654PubMedCrossRefGoogle Scholar
  212. Ollat H, Parvez H, Parvez S (1988) Alcohol and central neurotransmission. Neurochem Int 13: 275–300PubMedCrossRefGoogle Scholar
  213. Olivier B, Mos J, Rasmussen D (1990) Behavioural pharmacology of the serenic, eltoprazine. Drug Metab Drug Interact 8: 31–83Google Scholar
  214. Parsian A, Todd RD, Devor EJ, O’malley KL, Suarez BK, Reich T, Cloninger RC (1991) Alcoholism and alleles of the human D2 dopamine receptor locus. Arch Gen Psychiatry 48: 655–663PubMedCrossRefGoogle Scholar
  215. Peralta V, Cuesta MJ (1992) Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 85: 127–130PubMedCrossRefGoogle Scholar
  216. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediatet by K opiate receptors. Science 233: 774–776PubMedCrossRefGoogle Scholar
  217. Pietraszek MH, Urano T, Sumioshi K, Serizawa K, Takahashi S, Takada Y, Takada A (1991) Alcohol-induced depression: involvement of serotonin. Alcohol Aloholism 26: 155–159Google Scholar
  218. Post RM, Susan R, Weiss B (1992) Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 25: 41–43PubMedCrossRefGoogle Scholar
  219. Presslich O, Loimer N, Aschauer G, Fodor G, Pfersmann D, Müller K, Pakesch G, Lieber A (1989) Fraktionierter Opiatentzug mit Tiaprid and Naloxon, ein neuer Therapieansatz. Psychiat Prax 16: 179–181Google Scholar
  220. Regier LDA, Farmer ME, Rae DS et al. (1990) Co-morbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area ( ECA) study. JAMA 264: 2511–2518Google Scholar
  221. Resnick RB, Resnick E, Galanter M (1991) Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuro Psychopharmacol Biol Psychiatry 15: 531–538CrossRefGoogle Scholar
  222. Rezvani AH, Grady DR, Janowsky DS (1991) Effect of calcium-channel blockers on alcohol consumption in alcohol-drinking monkeys. Alcohol Alcoholism 26: 161–167Google Scholar
  223. Robbins SJ, Ehrman RN (1992) Designing studies of drug conditioning in humans. Psychopharmacology 106: 143–153PubMedCrossRefGoogle Scholar
  224. Ross HE, Glaser FB, Stiasny S (1988) Sex differences in the prevalence of psychiatric disorders in patients with alcohol and drug problems. Br J Addict 83: 1179–1192PubMedCrossRefGoogle Scholar
  225. Rou Renberg O (1988) Das Belohnungssystem des Gehirn. In: Gehirn und Nervensystem. Spektrum der Wissenschaft. Verlagsgemeinschaft Weinheim, S 161–167Google Scholar
  226. Roy A, Virkkunen M, Linnoila M (1987) Reduced central serotonin turnover in a subgroup of alcoholism. Prog Neuro Psychopharmacol Biol Psychiatry 11: 173–177CrossRefGoogle Scholar
  227. Roy A, Dejong J, Lamparski D, George T, Linnoila M (1991) Depression among alcoholics. Arch Gen Psychiatry 48: 428–432PubMedCrossRefGoogle Scholar
  228. San L, Pomarol G, Peri JM, Olle JM, Cami J (1991) Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 86: 983–990PubMedCrossRefGoogle Scholar
  229. Scherbaum N, Gastpar M (1991) Die Substitution mit Methadon als Therapieansatz in der Behandlung Opiatabhängiger. Nervenarzt 62: 529–535PubMedGoogle Scholar
  230. Schmidt LG, Rommelspacher H (1990) Biologische Marker des Alkoholismus. Nervenarzt 61: 140–147PubMedGoogle Scholar
  231. Schrappe O (1980) Toxikomanie. In: Peters UH (Hrsg) Die Psychologie des 20. Jahrhunderts, Bd X. Ergebnisse für die Medizin ( 2 ). Psychiatrie. Kindler, Zürich, S 849–868Google Scholar
  232. Schuckit MA (1986) Genetic and clinical implications of alcoholism and affective disorder. Am J Psychiatry 143: 140–147PubMedGoogle Scholar
  233. Schuckit MA (1987) Biology of risk for alcoholism. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 1527–1533Google Scholar
  234. Schuckit MA (1989) Drug and alcohol abuse. A clinical guide to diagnosis and treatment. Plenum, New YorkGoogle Scholar
  235. Segest E, Mygind O (1990) The influence of prolonged stable methadone maintenance treatment on mortality and employment: an 8-year follow-up. Int J Addict 25: 53–63PubMedGoogle Scholar
  236. Sellis SB (1981) Follow-up and treatment outcome. In: Lo’inson JH, Ruiz P (eds) Substance abuse: clinical problems and perspectives. Williams and Wilkins, Baltimore London, pp 783–800Google Scholar
  237. Shaw GK, Majumdar SK, Waller S, Macgarvie J, Dunn G (1987) Tiapride in the long-term ma- nagement of alcoholics of anxious or depres- sive temperament. Br J Pschiatry 150: 164–168CrossRefGoogle Scholar
  238. Shippenberg TS, Bals-Kubik R, Huber A, Herz A (1991) Neuroanatomical substrates mediating the aversive effects of D1—dopamine receptor antagonists. Psychopharmacology 103: 209–214PubMedCrossRefGoogle Scholar
  239. Snyder SH (1987) Molecular strategies in neuropsychopharmacology: old and new. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 17–21Google Scholar
  240. Stastny D, Potter M (1991) Alcohol abuse by patients undergoing methadone treatment programm. Br J Addict 86: 307–310PubMedCrossRefGoogle Scholar
  241. Steketee JD, Sorg BA, Kalivas PW (1992) The role of the nucleus accumbens in sensitization to drugs of abuse. Neuro Psychopharmacol Biol Psychiatry 16: 237–246CrossRefGoogle Scholar
  242. Strian F, Zieglgänzberger W, Holsboer F (1991) Neurobiologische Forschungsstrategien zur Alkoholkrankheit. In: Materialien zur Gesundheitsforschung. Schriftreihe zum Programm der Bundesregierung Forschung und Entwicklung im dienste der Gesundheit (Hrsg) Suchtforschung: Bestandsaufnahme und Analyse des Forschungsbedarfs. Bonn (Bd 19 ), S 50–64Google Scholar
  243. Sullivan JL, Baenziger JC, Wagner DL, Rauscher FP, Nurnbrger JI, Holmes JS (1990) Platelet MAO in subtypes of alcoholism. Biol Psychiatry 27: 911–922PubMedCrossRefGoogle Scholar
  244. Szmigielski A, Zalewska-Kaszubska J (1991) Cooperation between D,— and D2—dopamine receptors in the nucleus accumbens. Neuropharmacology 30: 259–266PubMedCrossRefGoogle Scholar
  245. Taschner KL (1991) Brauchen wir Methadonsubstitutionsprogramme? Nervenarzt: 62: 524–528PubMedGoogle Scholar
  246. Tollefson GD (1989) Serotonin and alcohol: interrelationships. Psychopathology 22 [Suppl]: 37–48PubMedCrossRefGoogle Scholar
  247. Tollefson GD, Lancaster SP, Montague-Clouse J (1991) The association of buspirone and its metabolite 1—pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol Bull 27: 163–170PubMedGoogle Scholar
  248. Topel H (1990) Perspektiven der Alkoholismus-Forschung der 90er Jahre. Suchtgefahren 36: 91–96Google Scholar
  249. Turner E, Ewing J, Shilling P, Smith TL, Irwin M, Schuckit M, Kelsoe JR (1992) Lack of association between an RFLP near the D2dopamine receptor gene and severe alcoholism. Biol Psychiatry 31: 285–290PubMedCrossRefGoogle Scholar
  250. Trudeau LE, Aragon CMG, Amit Z (1991) Involvement of endogenous opioid mechanisms in the interaction between stress and ethanol. Psychopharmacology 103: 425–429PubMedCrossRefGoogle Scholar
  251. Udego L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5—HT, receptor antagonist, activates mid-brain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45–50CrossRefGoogle Scholar
  252. Vining E, Kosten TR, Kleber HD (1988) Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 83: 567–575PubMedCrossRefGoogle Scholar
  253. Vogel WH, Netter P (1989) Effect of ethanol and stress on plasma catecholamines and their relation to changes in emotional state and performance. Alcoholism Clin Exp Res 13: 284–290CrossRefGoogle Scholar
  254. Watson SJ, Trujillo KA, Herman JP, AKIL H (1989) Neuroanatomical and neurochemical substrates of drug-seeking behaviour: overview and future directions. In: Goldstein A (ed) Molecular and cellular aspects of the drug addictions. Springer, Berlin Heidelberg New York Tokyo, pp 29–91CrossRefGoogle Scholar
  255. Weddington WW, Brown BS, Haertzen CA, Hess JM, Mahaffey JR, Kolar AF, Jaffe JH (1991) Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 17: 137–152PubMedCrossRefGoogle Scholar
  256. Weiss RD, Mirin SM (1989) Tricyclic antidepressants in the treatment of alcoholism and drug abuse. J Clin Psychiatry 50: 4–9PubMedGoogle Scholar
  257. Wikler A (ed) (1980) Opioid dependence. Mechanisms and treatment. Plenum Press, New York LondonGoogle Scholar
  258. Wise RA (1987) The role of reward pathways in the development of drug dependence. Pharmacol Ther 35: 227–263PubMedCrossRefGoogle Scholar
  259. Wittchen HU, Hand I, Hecht H (1989) Prävalenz, Komorbidität und Schweregrad von Angststörungen. Ergebnisse der Münchner Followup-Studie ( MFS ). Z KIM Psychol 18: 117–133Google Scholar
  260. Birmanns B, Clarenbach P (1989) Effect of serotonin receptor antagonists on sleep and sleep related release of HGH, prolactin and cortisol. In: Wauquier A et al. (eds) Slow wave sleep: physiological, pathophysiological and functional aspects. Raven, New York, pp 235–242Google Scholar
  261. Campbell M, Adams P, Small AM, Curren EL, Overall JE, Anderson LT, Lynch N, Perry R (1988) Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 4: 434–439CrossRefGoogle Scholar
  262. Ceulemans DLS, Hoppenbrouwers MLJA, Gelders YG, Ryntjens AJM (1985) The influence of ritanse- rin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18: 303–305PubMedCrossRefGoogle Scholar
  263. Cook EH JR, Leventhal BL, Freedman DX (1988) Free serotonin plasma: autistic children and their first-degree relatives. Biol Psychiatry 24: 488–491PubMedCrossRefGoogle Scholar
  264. Curzon G (1988) Serotonergic mechanism of depression. Clin Neuropharmacol 11 [Suppl 2]: 11–20Google Scholar
  265. Den Boer JA (1989) Serotonergic mechanism in anxiety disorders. An inquiry into serotonergic function in panic disorder. Pharmaceutisch Weekblad Scientific edition 11: 103–104CrossRefGoogle Scholar
  266. Doerish CT (1987) Brain 5-HT, receptors and anxiety. In: DouxisH CT et al. (eds) Brain 5-HT„ receptors. Ellis Howard, Chichester, pp 261–277Google Scholar
  267. Gelders Y (1989) Ritanserin: an original thymosthenic, 4th ed. Janssen Research Foundation, BeerseGoogle Scholar
  268. Gelernter J, Kammen DP (1988) Schizophrenia: instability in norepinephrine, serotonin, and gamma-aminobutyric acid systems. Int Rev Neurobiol 29: 309–347PubMedCrossRefGoogle Scholar
  269. Glennon RA (1990) Serotonin receptors: clinical implications. Neurosci Biobehav Rev 14: 35–47PubMedCrossRefGoogle Scholar
  270. Janssen PAJ (1987) Does ritanserin, a potent serotonin S2-antagonist, restore energetic functions during the night? J R Soc Med 80: 409–4413PubMedGoogle Scholar
  271. Leibowitz SF, Weiss GF, Shor-Posner G (1988) Hypothalamic serotonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action. Clin Neuropharmacol 11 [Suppl 11: 51–71Google Scholar
  272. Leonard BE (1988) Pharmacological effects of serotonin reuptake inhibitors. J Clin Psychiatry 49: 12–17PubMedGoogle Scholar
  273. Leysen JE, Van Gompel P, Gommeren W, Woesten-Borghs R, Janssen PAJ (1986) Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology 88: 434 444Google Scholar
  274. Marfk GJ, Li A, Seiden LS (1989) Selective 5hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinforcement of low rate 72-S schedule. J Pharmacol Exp Ther 250: 52–59Google Scholar
  275. Mcbride PA, Anderson GM, Hertzig ME, Sweeny JA (1989) Serotonergic responsivity in male young adults with autistic disorder. Arch Gen Psychiatry 46: 213–221PubMedCrossRefGoogle Scholar
  276. Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizol Y, Tanaka C (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21: 1407–1414PubMedCrossRefGoogle Scholar
  277. Paiva T, Arriaga F, Wauquier A, Lara E, Largo R, Leitao JN (1989) Changes in sleep disturbances of dysthymic patients induced by ritanserin. In: Wauquier A et al. (eds) Slow wave sleep: physiological, pathophysiological and functional aspects. Raven, New York, pp 217–234Google Scholar
  278. Pastel RH (1988) Effects of LY53857, a selective 5-HT2 antagonist, on sleep in the rat. Soc Neurosci Abstr 14: 1307Google Scholar
  279. Realmuto GM, August GJ, Garfinkel BD (1989) Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 9: 122–125PubMedCrossRefGoogle Scholar
  280. Reynolds GP, Arnold L, Rossor MN, Iversen LL, Mountjoy CQ, Roth M (1984) Reduced binding of (3H)ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type. Neurosci Lett 44: 47–51PubMedCrossRefGoogle Scholar
  281. Sanders-Bush E, Breeding M, Roznoski M (1987) 5HT2 binding sites after mianserin: comparison of loss of sites and brain levels of drug. Eur J Pharmacol 133: 199–204Google Scholar
  282. Silver H, Blacker M, Weller MPI, Lerer B (1989) Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 25: 502–504PubMedCrossRefGoogle Scholar
  283. Stanley M, Mann JJ (1983) Increased serotonin-2 binding sites in the frontal cortex of suicide victims. Lancet is 214–216Google Scholar
  284. Tricklebank MD (1989) Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 10: 129CrossRefGoogle Scholar
  285. Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates mid-brain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45–50PubMedCrossRefGoogle Scholar
  286. Watling KJ (1989) 5-HT3 receptor agonists and antagonists. Neurotransmission 5: 1–4Google Scholar
  287. Akerman KEO, Heinonen E (1983) Qualitative measurement of cytosolic calciumion concentration within isolated guinea-pig nerve endings using entrapped arsenazo. Biochem Biophys Acta 732: 111–121Google Scholar
  288. Allen GS, Goss CJ, French LA, Chou SN (1976) Cerebral arterial spasm. Part 5. In vitro contractile activity of vasoactive agents including human cerebrospinal fluid on human basilar and anterior cerebral arteries. J Neurosurg 6: 63–70Google Scholar
  289. Allen GS, Ahn HS, Preziosi TJ et al. (1983) Cerebral arterial spasm–a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308: 619–624PubMedCrossRefGoogle Scholar
  290. Alps BJ, Calder C, Wilson A (1983) The beneficial effect of nicardipine compared with nifedipine and verapamil in limiting myocardial infarct size in baboons. Arzneimittelforschung 33: 868–876PubMedGoogle Scholar
  291. Amery WK, Cares LI, Aerts WJL (1985) Flunarizine, a calcium entry blocker in migraine prophylaxis. Headache 25: 249–254PubMedCrossRefGoogle Scholar
  292. Ames A III, Wright RL, Kowada M, Thurston JM, Majno G (1968) Cerebral ischemia. II. The noreflow phenomenon. Am J Pathol 52: 437–453Google Scholar
  293. Anthony M, Hinterberger H, Lance JW (1968) Studies of serotonin metabolism in migraine. Proc Austr Assoc Neurol 5: 109–112Google Scholar
  294. Asplund K, Eriksson S (1987) Scandinavian Stroke Study Group: multicenter trial of hemodilution in acute ischemic stroke. In: Hartmann A, Kuschinsky W (eds) Cerebral ischemia and hemorheology. Springer, Berlin Heidelberg New York Tokyo, pp 472–486CrossRefGoogle Scholar
  295. Astrup J, Siesjö BK, Symon L (1981) Thresholds in cerebral ischemia: the ischemic penumbra. Stroke 12: 723–725PubMedCrossRefGoogle Scholar
  296. Auer LM (1981) Pial arterial vasodilatation by intravenous nimodipine in cats. Drug Res 31: 1423–1425Google Scholar
  297. Auer ML (1983) Cerebrovascular activity of the calcium antagonist nimodipine. In: Reivich M, Hurtig S (eds) Cerebrovascular diseases. Raven Press, New York, pp 375–384Google Scholar
  298. Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, Caglieris N, Steriicchio M, Capurso A, Tomasi NA, Crepaldi G, Volpe D, Palmieri G, Ambrosi G, Polli E, Cortellaro M, Zanussi C, Froldi M (1990) Nimodipine in the treatment of old age dementias. Prog Neuro Psychopharmacol Biol Psychiatry 14: 525–551CrossRefGoogle Scholar
  299. Barrett JN, Magelby KL, Pallotta BS (1982) Properties of single calcium activated potassium channels in cultured rat muscle. J Physiol 331: 211–230PubMedGoogle Scholar
  300. Blass JP, Zemcov A (1984) Alzheimer disease: a metabolic systems degeneration. Neurochem Pathol 2: 103–114PubMedCrossRefGoogle Scholar
  301. Blaustein MP (1974) Interrelationship between sodium and calcium fluxes across cell membranes. Rev Physiol Biochem Pharmacol 70: 33–82PubMedCrossRefGoogle Scholar
  302. Böker DK, Solymosi L, Wassmann H (1985) Immediate postangiographic intraarterial treatment of cerebral vasospasm after subarachnoid hemorrhage with nimodipine. Neurochirurgi-ca 28: 118–120Google Scholar
  303. Boni G, Manzioni GC, Matrucci N, Baldrati A, Farina S, Cassabgi F, Decarolis P, Nappi G Flunarizine in common migraine: Italian cooperative trial. II. Long-term follow-up. Cephalalgia 2: 155–158Google Scholar
  304. Bourke RS, Kimelberg HG (1975) The effect of HCO3 on the swelling and ion uptake of monkey cerebral cortex under conditions of raised extracellular potassium. J Neurochem 25: 323–328PubMedCrossRefGoogle Scholar
  305. Brandt L, Anderson KE, Edvinsson L, Ljunggren B (1981) Effects of extracellular calcium and of calcium antagonists on the contractile responses of isolated human pial and mesenteric arteries. J Cereb Blood Flow Metab I: 339–347Google Scholar
  306. Branston NM, Strong AJ, Symon L (1977) Extracellular potassium activity, evoked potential and tissue blood flow: relationships during progressive ischaemia in baboon cerebral cortex. J Neurol Sci 32: 305–321PubMedCrossRefGoogle Scholar
  307. Brody IA (1969) Muscle contracture induced by exercise. N Engl J Med 281: 187–192PubMedCrossRefGoogle Scholar
  308. Campbell AK (1983) Intracellular calcium: its universal role as regulator. Wiley, New YorkGoogle Scholar
  309. Carbone E, Lux HD (1984) A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurones. Nature 310: 501–502Google Scholar
  310. Castillo J Del, Katz B (1954) Quantal components of the end plat potential. J Physiol 124: 560–573Google Scholar
  311. Cheung WY (1982) Calmodulin: an overview. Fed Proc 41: 2253–2257PubMedGoogle Scholar
  312. Caongdon PJ, Forsrre WI (1979) Migraine in childhood: a study of 300 children. Dev Med Child Neurol 21: 209–216CrossRefGoogle Scholar
  313. Cortes R, Supavilai P, Karobath M, Palacios JM (1984) Calcium antagonist binding sites in the rat brain: quantitative autoradiographic mapping using the 1,4—dihydropyridines (3H)PN 200–110 and (3H)PY 108–068. J Neural Transm 60: 169–197PubMedCrossRefGoogle Scholar
  314. Crompton MR (1964) The pathogenesis of cerebral infarction following the rupture of cerebral berry aneurysms. Brain 87: 491–510PubMedCrossRefGoogle Scholar
  315. Danon MJ, Karpati G, Charuk J, Holland P (1988) Sarcoplasmatic reticulum adenosine triphos- phate deficiency with probably autosomal dominant inheritance. Neurology 38: 812–814PubMedCrossRefGoogle Scholar
  316. Delorenzo RJ (1983) Caclium-calmodulin protein phosphorylation in neuronal transmission: a molecular approach to neuronal excitability and anticonvulsant drug action. Adv Neurol 34: 311–323Google Scholar
  317. Demopoulos HB, Flamm ES, Pietronigro DD, Selig-Man ML (1980) The free radical pathology and the microcirculation in the major central ner- vous disorders. Acta Physiol Scand 492: 91–119Google Scholar
  318. Deshmukh SV, Meyer JS (1977) Cyclic change in platelet dynamics and the pathogenesis and prophylaxis of migraine. Headache 17: 101–108PubMedCrossRefGoogle Scholar
  319. Dick DJ, Gardner-Medwin D, Gates PG, Gibson M, Walls TJ (1986) A trial of flunarizine in the treatment of Duchenne muscular dystrophy. Muscle Nerve 9: 349–354PubMedCrossRefGoogle Scholar
  320. Dunlap K, Fischbach GD (1981) Neurotransmitters decrease the calcium conductance activated by depolarization of embryonic chick sensory neurones. J Physiol 317: 519–535PubMedGoogle Scholar
  321. Eckert R, Chad JE (1984) Inactivation of Ca chan- nels. Prog Biophys Mol Bio144: 215–267Google Scholar
  322. Elbaz P, Haguenauer JP, Muler H, Portmann M (1986) Activite therapeutique d’un inhibiteur de la surcharge calcique, la flunarizine, dans les troubles vestibulaires: etude a double insu contra placebo. ORL 35: 301–308Google Scholar
  323. Ell J, Gresty M (1983) The effects of the “vestibular sedative” drug flunarizine upon the vestibular and oculomotor systems. J Neurol Neurosurg Psychiatry 46: 716–724PubMedCrossRefGoogle Scholar
  324. Eppich C, Barnes CA, Baldwin J (1985) 3,4-Dia-minopyridine improves spatial working me- mory but not spatial reference memory in aged rats. Soc Neurosci Abstr 11: 724Google Scholar
  325. Fisher CM, Robertson GH, Olemann G (1984) Cerebral vasospasm with ruptured saccular aneurysm — the clinical manifestation. Neurosurgery 1: 245–248CrossRefGoogle Scholar
  326. Flaim SF (1982) Comparative pharmacology of calciumblockers based on studies of vascular smooth muscle. In: Flaim SF, Zeus R (eds) Calcium blockers: mechanism of action and clinical applications. Urban & Schwarzenberg, Baltimore, pp 155–178Google Scholar
  327. Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17: 149–166CrossRefGoogle Scholar
  328. Fraser RAR, Stein MM, Barrett RE, Pool JL (1970) Noradrenergic mediation of experimental cerebrovascular spasm. Stroke 1: 356–362PubMedCrossRefGoogle Scholar
  329. Freedman SB, Dawson G, Villereal ML, Miller RJ (1984) Identification and characterization of voltage-sensitive calcium channels in neuronal clonal cell lines. J Neurosci 4: 1453–1467PubMedGoogle Scholar
  330. Freeman GB, Gibson GE (1986) Selective alteration of neurotransmitter release with aging. Soc Neurosci Abstr 12: 271Google Scholar
  331. Frenken CWGM, Nuijten STM (1984) Flunarizine, a new preventive approach in migraine. Clin Neurol Neurosurg 86: 17–20PubMedCrossRefGoogle Scholar
  332. Fijisawa A, Matdsumoto M, Matsltyama T, Ueda H, Wanaka W, Yoneda S, Kimura K, Kamada T (1986) The effect of the calcium antagonist nimodipine on the gerbil model of experimental cerebral ischemia. Stroke 17: 748–752CrossRefGoogle Scholar
  333. Gaab RM, Rode C-P, Schakel EH, Haubitz I, Bock-Horn J, Brawanski A (1985) Zum Einfluß des Ca-Antagonisten Nimodipin auf die globale and regionale Hirndurchblutung. Klin Wochenschr 83: 8–15CrossRefGoogle Scholar
  334. Garb MR, Hollerhage HG, Zumkeller M, Trost HA (1987) The effect of the Ca antagonist nimodipine on cerebral blood flow autoregulation. J Cereb Blood Flow Metab 7: 170Google Scholar
  335. Gallant EM, Foldes FF, Rempel WE, Gronert GA (1985) Verapamil is not a therapeutic adjunct to dantrolene in porcine malignant hyperthermia. Anaesth Anal 64: 601–606Google Scholar
  336. Gardos G (1958) The function of calcium in the potassium permeability of human erythrocytes. Biochem Biophys Acta 30: 653–654PubMedCrossRefGoogle Scholar
  337. Garruto RM, Fukatsu R, Yanagihara R, Gajdusek DC, Hook G, Fiori CE (1984) Imaging of calcium and aluminium in neurofibrillary tangle-bearing neurons in Parkinsonism-dementia of Guam. Proc Natl Acad Sci USA 81: 1875–1879PubMedCrossRefGoogle Scholar
  338. Gelmers HJ (1982) Effect of nimodipine (Bay-9736) on postischaemic cerebrovascular reactivity, as revealed by measuring regional cerebral blood flow (rCBF). Acta Neurochir (Wien) 63: 283–290CrossRefGoogle Scholar
  339. Gelmers HJ (1983) Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache 23: 106–109PubMedCrossRefGoogle Scholar
  340. Gelmers HJ, Gorter K, De Weerdt CJ, Wiezer HJ (1988) A controlled trial of nimodipine in acu- te ischemic stroke. N Engl J Med 318: 203–207PubMedCrossRefGoogle Scholar
  341. Ginsberg MD, Mela L, Wrobel Kuhl K, Reivich M (1977) Mitochondrial metabolism following bilateral cerebral ischemia in the gerbil. Ann Neurol 1: 519–527PubMedCrossRefGoogle Scholar
  342. Goldensohn ES, Purpura DP (1963) Intracellular potentials of cortical neurons during focal epileptogenic discharges. Science 139: 840–842PubMedCrossRefGoogle Scholar
  343. Gould RJ, Murphy KMM, Snyder SH (1982) Autoradiographic visualization of (3H)-nitrendipine binding sites in rat brain: localization to synaptic zones. Eur J Pharmacol 82: 517–519Google Scholar
  344. Gould RJ, Murphy KMM, Reynolds U, Snyder SH (1984) Calcium channel blockade: possible explanation for thioridazine’s peripheral side effects. Am J Psychiatry 141: 352–357PubMedGoogle Scholar
  345. Greenberg DA, Carpenter CL, Cooper EC (1985) Stimulation of calcium uptake in PC12 cells by the dihydropyridine agonist BAY K 8644. J Neurochem 45: 990–993PubMedCrossRefGoogle Scholar
  346. Gronert GA, Mou J, Lee J (1988) Aetiology of malignant hyperthermia. Anaesth 60: 253–267CrossRefGoogle Scholar
  347. Grubb RL, Raichle ME, Eichlin JO, Gado MH (1977) Effect of subarachnoid hemorrhage on cere- bral blood volume, blood flow and oxygen utilisation in humans. J Neurosurg 46: 446–453PubMedCrossRefGoogle Scholar
  348. Guerrero JR, Martin SS (1984) Verapamil: full spectrum calcium channel blocking agent: an overview. Med Res Rev 4: 87–109PubMedCrossRefGoogle Scholar
  349. Harper AM, Braigen L, Karda S (1981) Effect of the calcium antagonist, nimodipine, in cerebral blood flow and metabolism in the primate. J Cereb Blood Flow Metab 1: 349–356PubMedCrossRefGoogle Scholar
  350. Harris RJ, Symon L, Branston NM, Bayan M (1981) Changes in extracellular calcium activity in cerebral ischaemia. J Cereb Blood Flow Me-tab 1: 203–209CrossRefGoogle Scholar
  351. Harris RJ, Branston MM, Symon L, Bayhan M, Wat-Son A (1982) The effect of a calcium antagonist, nimodipine, upon physiological responses of the cerebral vasculature and its possible influence upon focal cerebral ischemia. Stroke 13: 759–766PubMedCrossRefGoogle Scholar
  352. Hartmann A (1987) Die Bedeutung der Rheologie für zerebrale Durchblutungsstörungen. Akt Neurol 14: 35–41CrossRefGoogle Scholar
  353. Hartmann A (1987) Die Hämodilution beim zerebralen Insult. Akt Neurol 14: 42–49CrossRefGoogle Scholar
  354. Hartmann A (1988) Die Gehirndurchblutung bei der Migräne. In: Soyka D (Hrsg) Klinische Kopfschmerzsyndrome. Fischer, Stuttgart New York, S 33–44Google Scholar
  355. Havanka-Kanniainen H, Hokkanen E, Myllyka VV (1985) Efficacy of nimodipine in the prophylaxis of migraine. Cephalgia 5: 39–43CrossRefGoogle Scholar
  356. Heffez DS, Passoneau JV (1985) Effect of nimodipine on cerebral metabolism during ischemia and recirculation in the mongolian gerbil. J Cereb Blood Flow Metab 5: 523–528PubMedCrossRefGoogle Scholar
  357. Heiss WD (1983) Flow thresholds of functional and morphological damage of brain tissue. Stroke 14: 329–331PubMedCrossRefGoogle Scholar
  358. Hess P, Landsman JB, Tsien RW (1984) Different modes of Ca channel gating behavior favoured by dihydropyridine Ca agonist and antagonists. Nature 311: 538–544PubMedCrossRefGoogle Scholar
  359. Hilles B (1984) Ionic channels of excitable membranes. Sinauer Associates, Sunderland MassGoogle Scholar
  360. Hofferberth B (1986) Calcium entry blockers in the treatment of vertebro-basilar insufficiency. Eur Neurol 25: 80–85PubMedCrossRefGoogle Scholar
  361. Holmes B, Brogden RN, Heel C, Speight TM, AVERY GS (1984) Flunarizine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 27: 6 44Google Scholar
  362. Hossman KA, Paschen W, Csiby L (1983) Relation-ship between calcium accumulation and re- covery of cat brain after prolonged cerebral ischemia. J Cereb Blood Flow Metab 3: 346–353CrossRefGoogle Scholar
  363. Jacoss MB (1983) Diltiazem and akathisia. Ann Intern Med 99: 794–795Google Scholar
  364. Kahan A, Weber S, Amor B, Guerin F, Degeorges M (1983) Nifedipine in the treatment of migraine in patients with Raynaud’s phenomenon. N Engl J Med 308: 1102–1103PubMedGoogle Scholar
  365. Kalls P (1977) Uptake and release of calcium in rabbit vagus nerve. Pflügers Arch 326: 1–14Google Scholar
  366. Karpati G, Charuk J, Carpenter S, Jablecki C, Hol-Land P (1986) Myopathy caused by a deficiency of Ca“ ATPase in sarcoplasmatic reticulum ( Brody’s disease ). Ann Neurol 20: 38–49Google Scholar
  367. Kassell NF, Sasaki T, Colohan ART, Nayar G (1985) Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 16: 562–572PubMedCrossRefGoogle Scholar
  368. Kazda S, Garthoff B, Krause HP, Schlossmann K (1982) Cerebral vascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung 2: 331–338Google Scholar
  369. Kimball RW, Goodmann MA (1961) Effects of reserpine on amino acid excretion in patients with vascular headaches. Neurology (Minneapolis) 11: 116CrossRefGoogle Scholar
  370. Kur A, Elder B, Ruiz-Funes HP, Buchwald M, Grin-Stein (1985) The free cytoplasmatic Ca“-levels in Duchenne muscular dystrophy lymphocytes. Muscle Nerve 8: 317–320Google Scholar
  371. Koos WT, Pernezky A, Auer LM, Böker DB, Gaab MR, Jaschke H, Kostron H, Meinig G, Muizellar JP, Van Der Werft AJM, Seibert HK, Ulrich F, Sprung C (1985) Nimodipine treatment of ischemic neurological deficits due in cerebral vasospasms after subarachnoid hemorrhage. Neurochirurgica 28: 114–117Google Scholar
  372. Lauritzen M, Olsen J (1984) Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 107: 447–461PubMedCrossRefGoogle Scholar
  373. Lauritzen M, Skyhoj Olsen T, Lassen NA, Paulson OB (1983) Changes in regional cerebral blood flow during the course of classical migraine attacks. Ann Neurol 13: 633–641PubMedCrossRefGoogle Scholar
  374. Lead AAP (1944) Spreading depression of activity in cerebral cortex. J Neurophysiol 7: 359–390Google Scholar
  375. Lee KS, Tsien RW (1986) Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 302: 790–794CrossRefGoogle Scholar
  376. Lee JA, Watson A, Boothby G (1986) Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 57: 45–48PubMedGoogle Scholar
  377. Lehmenkühler A (1979) Interrelationship between CD potentials, potassium activity, pO2 and pCO2 in the cerebral cortex of the rat. In: Speckmann EJ, Caspers H (eds) Origin of cerebral field potentials. Thieme, Stuttgart, pp 49–59Google Scholar
  378. Lewis JG (1983) Adverse reactions to calcium antagonists. Drugs 25: 196–222PubMedCrossRefGoogle Scholar
  379. Li CL, Van Buren JM (1972) Micro-electrode recordings in the brain of man with particular reference to epilepsy and dyskinesia. In: Somjen GG (ed) Neurophysiology studied in man. Excerpta Medica, Amsterdam, pp 49–63Google Scholar
  380. Ljunggren B, Brandt L, Saeveland H, Nilsson PE et al. (1984) Outcome in 60 consecutive patients treated with early aneurysm operation and intravenous nimodipine. J Neurosurg 67: 864 873Google Scholar
  381. Lopez JR, Allen PD, Alamo L, Jones D, Sreter FA (1988) Myoplasmic free Ca“ during a malignant hypertheramia episode in swine. Muscle Nerve 11: 82–88PubMedCrossRefGoogle Scholar
  382. Louis P (1981) A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 21: 235–239PubMedCrossRefGoogle Scholar
  383. Louis P, Sperings ELH (1982) Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalgia 2: 197–203CrossRefGoogle Scholar
  384. Lüllmann H, Peters TH (1977) Plasmalemmal calcium in cardiac excitation-contradiction coupling. Clin Exp Pharmacol Physiol 4: 49–57PubMedCrossRefGoogle Scholar
  385. Lüllmann H, Peters TH, Preuner J (1983) Role of the plasmalemma for calcium homeostasis and for excitation-contraction coupling in cardiac musle. In: Drake N, Holland S, Noble M (eds) Cardiac metabolism. Wiley, Chichester, pp 1–18Google Scholar
  386. Lux HD, Hofmeier G (1982) Properties of calcium-and voltage-activated potassium current in helix pomatia neurons. Pflügers Arch 394: 61–59PubMedCrossRefGoogle Scholar
  387. Markley HG, Cheronis JCD, Piepho RW (1984) Verapamil in prophylactic therapy of migraine. Neurology 34: 973–976PubMedCrossRefGoogle Scholar
  388. Matsumuto H, Ajmone Marsan C (1964) Cortical cellular phenomena in experimental epilepsy: interictal manifestations. Exp Neurol 9: 286–304CrossRefGoogle Scholar
  389. Matthews EK (1986) Calcium and membrane permeability. Br Med Bull 42: 391–397PubMedGoogle Scholar
  390. Meech RW (1978) Calcium-dependent potassium activation in nervous tissues. Ann Rev Biophys Bioeng 7: 1–18CrossRefGoogle Scholar
  391. Mendenopoulos G, Manafi T, Logothesis 1, Bostant-Joroulou S (1985) Flunarizine in the prevention of classical migraine. A placebo controlled evaluation. Cephalalgia 5: 31–37Google Scholar
  392. Meyer EM, Baker SP, Crews FT, Larsen K (1985) Aging and acetylcholine-release from cortical synaptosomal and atrial minces. Soc Neurosci Abstr 11: 980Google Scholar
  393. Meyer FB, Anderson RE, Sundt TM Jr, Yaksh TL (1986) Intracellular brain pH, indicator tissue perfusion, electroencephalography, and histology in severe and moderate focal cortical ischemia in the rabbit. J Cereb Blood Flow Metab 1: 190–191Google Scholar
  394. Meyer FB, Anderson RE, Sund TM Jr, Sharbrough FW (1986) Selective central nervous system calcium channel blockers–a new class of anticonvulsive agents. Mayo Clin Press 61: 239–247CrossRefGoogle Scholar
  395. Meyer JS, Hardenberg J (1983) Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headache. Headache 23: 266–277PubMedCrossRefGoogle Scholar
  396. Micieli O, Trucco M, Agostinis C, Macuso A, Papalia F, Sinforiani E (1985) Nimodipine vs. pizotifen in common migraine: results of a double blind cross-over trial. Cephalagia 5: 532–533Google Scholar
  397. Miller RJ (1985) How many types of calcium channels exist in neurones? Trends Neurosci 8: 45–47CrossRefGoogle Scholar
  398. Miller JR (1987) Multiple calcium channels and neuronal function. Science 235: 46–52PubMedCrossRefGoogle Scholar
  399. Mohamed AA, Gotch O, Graham DI, Osborne KA, Mcculloch J, Mendelow AD, Teasdale GM, Harper AM (1985) Effect of pretreatment with the calcium antagonist nimodipine on local cerebral blood flow and histopathology after middle cerebral artery occlusion. Ann Neurol 18: 705–711PubMedCrossRefGoogle Scholar
  400. Mongini T, Ghigo D, Doriguzzi C, Bussolino F, Pascarmona G, Pollo B, Schiffer D, Bosia A (1988) Free cytoplasmatic Ca“ at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. Neurology 38: 476–480PubMedCrossRefGoogle Scholar
  401. Moxley RT, Brooke MH, Fenichel GM, Mendell JR, Griggs RC, Miller JP, Province MA, Patterson V (1987) Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine Muscle Nerve 10: 22–33Google Scholar
  402. Murphy KMM, Gould RJ, Largent BL, Snyder SH (1983) A unitary mechanism of calcium antagonist drug action. Proc Natl Acad Sci USA 80: 860–864PubMedCrossRefGoogle Scholar
  403. Murphy SN, Miller RJ (1988) A glutamate receptor regulates Cat+ mobilization in hippocampal neurons. Proc Natl Acad Sci USA 85: 8737–8741PubMedCrossRefGoogle Scholar
  404. Newberg LA, Steen PA, Milde JH, Michenfelder JD (1984) Failure of flunarizine to improve cerebral blood flow or neurologic recovery in a canine model of complete cerebral ischemia. Stroke 13: 666–671CrossRefGoogle Scholar
  405. Nishizuka Y (1984) Turnover of inositol phospholipide and signal transduction. Science 225: 1365–1370PubMedCrossRefGoogle Scholar
  406. Nowycky MC, Fox AP, Tsien RW (1985) Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 316: 440–443PubMedCrossRefGoogle Scholar
  407. Olesen J, Larsen B, Lauritzen M (1981) Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 9: 344–352PubMedCrossRefGoogle Scholar
  408. Oosterveld D (1982) Flunarizine in vertigo. A double-blind placebo-controlled crossover evaluation of a constant-dose schedule. ORL 44: 72–80PubMedCrossRefGoogle Scholar
  409. Oosterveld WJ (1974) Vestibular pharmacology of flunarizine compared to that of cinnarizine. ORL 36: 157–164PubMedCrossRefGoogle Scholar
  410. Overweg J, Ashton D, DE Beukelaar F, Binnie Wau-Quier A (1986) Add-on therapy in epilepsy with calcium entry blockers. Eur Neurol 25: 93–101PubMedCrossRefGoogle Scholar
  411. Paskin NH (1981) Pharmacology of migraine. Ann Rev Pharmacol Toxicol 21: 463–478CrossRefGoogle Scholar
  412. Peerless SJ, Kassell NF, Komatsu K, Hunter IG (1980) Cerebral vasospasm: acute proliferative vasculopathy? II. Morphology. In: WILKINS RH (ed) Cerebral arterial spasm. Williams & Wilkins, Baltimore, pp 88–96Google Scholar
  413. Pelletieri L, Carlson CA, Lindholm L (1981) Is the vasospasm following subarachnoid hemorrhage an immunoreactive disease? Experientia 15: 1170–1171CrossRefGoogle Scholar
  414. Pennefather K, Lancaster B, Adams PR, Nicoll RA (1986) Two distinct Ca-dependent K currents in bullfrog sympathetic ganglion cells. Proc Natl Acad Sci USA 82: 3040–3044CrossRefGoogle Scholar
  415. Peroutka SJ, Allen GS (1983) Calcium-channel antagonist binding sited labeled by 3H-nimodipine in human brain. J Neurosurg 59: 933–937PubMedCrossRefGoogle Scholar
  416. Peterson C, Gibson GE (1983) Aging and 3,4—diaminopyridine alter synaptosomal calcium uptake. J Biol Chem 258: 11482–11485PubMedGoogle Scholar
  417. Peterson C, Goldman JE (1986) Alterations in calcium content and biochemical processses during aging and Alzheimer disease. Proc Natl Acad Sci USA 83: 2758–2762PubMedCrossRefGoogle Scholar
  418. Peterson C, Ratan RR, Shelanski ML, Goldman JE (1986) Cytosolic free calcium and cell spreading decreases in fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci USA 83: 7999–8001PubMedCrossRefGoogle Scholar
  419. Prentki M, Biden TJ, Janjic D, Irvine RF, Berridge MJ, Wdllheim CB (1984) Rapid mobilization of Ca“’ from rat insulinoma microsomes by ionositol-1,4,5—triphosphate. Nature 309: 562–564PubMedCrossRefGoogle Scholar
  420. Rascol A, Montastruc JL, Rascol O (1985) Flunarizine versus pizotifen: a double blind study in the prophylaxes of migraine. Cephalalgia 5: 542Google Scholar
  421. Rasmussen H, Waismann DM (1983) Modulation of cell function in the calcium messenger system. Rev Physiol Biochem Pharmacol 95: 111–148CrossRefGoogle Scholar
  422. Reynolds IL Gould RJ, Snyder SH (1984) Loperamide: blockade of calcium channels as a mechanism for antidiarrheal effects. J Pharmacol Exp Ther 231: 628–632Google Scholar
  423. Roy MW, Dempsey RJ, Meyer KL, Donaldson DL, Tibbs PA, Young AB (1985) Effects of verapamil and diltiazem on acute stroke in cats. J Neurosurg 63: 929–936PubMedCrossRefGoogle Scholar
  424. Ryan US (1983) Endothelial cells and inflammation. Clin Lab Med 3: 577–599PubMedGoogle Scholar
  425. Sakai F, Meyer JS (1978) Regional cerebral hemodynamics during migraine and cluster headaches measured by the 133—Xe inhalation method. Headache 18: 122–132PubMedCrossRefGoogle Scholar
  426. Scherer H, Schmidtmayer E, Hirche H (1978) Die Wirkung von Bencyclan, Flunarizin and Naftridrofuryl auf den Nystagmus eines kalorischen Dauerreizes. Laryngol Rhinol Otol 57: 773–798Google Scholar
  427. Schwartz AC (1985) Neurological recovery after cardiac arrest: clinical feasibility trial of calcium blockers. Am J Emerg Med 3: 1–10PubMedCrossRefGoogle Scholar
  428. Seiler R, Grolimund P, Weber M (1988) Effect of nimodipine on the CO2 reactivity of patients with aneurysmatil subarachnoid hemorrhage. International Workshop: Cerebral Ischemia and Calcium. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  429. Shader RI, Dimascio A (1970) Psychotropic drug side effects: clinical and theoretical perspectives. Williams & Wilkins, BaltimoreGoogle Scholar
  430. Sharbrough FW, Messick JM JR, Sundt TM Jr (1973) Correlation of continuous electroencephalograms with cerebral blood flow measurements during carotid endarterectomy. Stroke 4: 674–683PubMedCrossRefGoogle Scholar
  431. Shearman GT (1989) Effect of NMDA antagonist MK-801 in animal models of focal and global cerebral ischemia. In: Ginsberg MD, Dietrich WD (eds) Cerebrovascular diseases. 16th Princetone Conference. Raven Press, New York, pp 73–78Google Scholar
  432. Siesjö BK (1982) Lactic acidosis in the brain: occurrence, triggering mechanisms and pathophysiological importance. Ciba Found Symp 87: 77–100PubMedGoogle Scholar
  433. Siesjö BK (1984) Cerebral circulation and metabolism. J Neurosurg 60: 883–908PubMedCrossRefGoogle Scholar
  434. Siesjö BK, Wieloch T (1985) Molecular mechanisms of ischemic brain damage: Cat..-related events. In: Plum P, Pulsinelli L (eds) Cerebro-vascular disease. 13th Research Conference, Princetone. Raven Press, New York, pp 187–197Google Scholar
  435. Skinho JE (1973) Hemodynamic studies within the brain during migraine. Arch Neurol (Chicago) 29: 95–98CrossRefGoogle Scholar
  436. Smith R, Schwartz A (1984) Diltiazem prophylaxis in refractory migraine. N Engl J Med 310: 1327–1328PubMedCrossRefGoogle Scholar
  437. Solaro RJ (1982) The role of calcium in the concentration of the heart. In: Flaim SF, Zelis R (eds) Calcium blockers. Urban & Schwarzenberg, Baltimore, pp 21–36Google Scholar
  438. Solomon GD, Steel JG, Spaccavento LJ (1983) Verapamil prophylaxes of migraine: a double-blind, placebocontrolled study. JAMA 250: 2500–2502PubMedCrossRefGoogle Scholar
  439. Somlyo AV, Bond M, Somlyo AP, Scarpa A (1985) Inositol triphosphate-induced calcium relea- se and contraction in vascular smooth muscle. Proc Natl Acad Sci USA 82: 5231–5235PubMedCrossRefGoogle Scholar
  440. Sorge F, Desimone R, Marano E, Orefice G, Carrieri P (1985) Efficacy of flunarizine in the pro- phylaxis of migraine in children. Cephalalgia 5: 172Google Scholar
  441. Staessen AJ (1977) Treatment of circulatory disturbances with flunarizine and cinnarizine. VASA 6: 59–71PubMedGoogle Scholar
  442. Stanfield PR (1986) Voltage-dependent calcium-channels of escitable membranes. Br Med Bull 42: 359–367PubMedGoogle Scholar
  443. Steen PA, Newberg LA, Milde JH, Michenfelder JD (1983) Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog. J Cereb Blood Flow Metab 3: 38–43PubMedCrossRefGoogle Scholar
  444. Strong AJ, Tomlinson BE, Venables GS, Gibson G, Hardy JA (1983) The cortical ischaemic penumbra associated wirth occlusion of the middle cerebral artery in the cat. 2. Studies of histopathology, water content, and in vivo neurotransmitter uptake. J Cereb Blood Flow Metab 3: 97–108Google Scholar
  445. Summers WK, Majovski LV, Marsh GM, Takichi K, Kling A (1986) Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241–1245Google Scholar
  446. Suzuki J, Kodama N, Yosjimoto, Mizoi K (1982) Ultraearly surgery of intracranial aneurysms. Acta Neurochir 83: 186–191Google Scholar
  447. Symon L, Ackermann R, Bull JWD et al. (1972) The use of the xenon clearance method in subarachnoid hemorrhage. Post-operative studies with clinical and angiography correlation. Eur Neurol 8: 8–14Google Scholar
  448. Symon L, Branston NM, Strong AJ, Hope TD (1977) The concept of thresholds of ischaemia in relation to brain structure and function. J Clin Pathol 30: 149–154CrossRefGoogle Scholar
  449. Taneda M (1982) Effect of early operation for ruptured aneurysms on prevention of delayed ischemic symptoms. J Neurosurg 57: 622–627PubMedCrossRefGoogle Scholar
  450. Teasdale G, Pickard J, Shaw D, Illingworth R (1989) Treatment of subarachnoid hemorrhage with calcium-antagonist: large randomized controlled trial. In: Hartmann A, Kuschinski W (eds) Cerebral ischemia and calcium. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  451. Thesleff S (1981) Aminopyridines and synaptic transmission. Neuroscience 5: 1413–1419CrossRefGoogle Scholar
  452. Theunissen EJJM, Huvgen PLM, Nicolasen MGM (1986) Flunarizine treatment in dizzy patients with vestibular hyperactivity and hyperventilation. ORL 48: 203–208PubMedCrossRefGoogle Scholar
  453. Turner JS (1977) The dizzy patient: diagnosis and treatments. Drugs 13: 382–387PubMedCrossRefGoogle Scholar
  454. Vanhouite PM, Paoletti R (1987) The Who classification of calcium antagonists. TIPS 8: 4–5Google Scholar
  455. Vermeulen M, Lindsy KW, Murray GD, Gheahf, Hijdra A, Muizelaar JP, Schannong M, Teasdale GM, Van Grevel H, Van Gijn J (1984) Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 311: 432–437PubMedCrossRefGoogle Scholar
  456. Voldby B, Peterson OF, Buhl M, Jakobsen P, Oster-Gaard R (1984) Reversal of cerebral arterial spasm by intrathecal administration of a calcium antagonist (nimodipine). Acta Neurochir (Wien) 70: 243–254CrossRefGoogle Scholar
  457. Weir BA (1980) The incidence and onset of vasospasm after subarachnoid hemorrhage from ruptured aneurysm. In: Wilkins RH (ed) Cerebral arterial spasm. Williams & Wilkins, Baltimore, pp 302–305Google Scholar
  458. Welsh FA, O’connor MJ, Marcy VR, Spatacco AJ, Johns RL (1982) Factors limiting regeneration of ATP following temporary ischemia in cat brain. Stroke 13: 234–242PubMedCrossRefGoogle Scholar
  459. Wesseling H, Agoston S, Van Dam GB, Pasma J, De Wrr DJ, Havinga H (1984) Effects of 4-aminopyridine in elderly patients with Alzheimer’s disease. N Engl J Med 310: 988–989PubMedCrossRefGoogle Scholar
  460. White BC, Gadzinski DS, Hoehner PJ, Krone C, Hoener T, White DJ, Trombley JH (1982) Effect of flunarizine on canine cerebral cortical blood flow and vascular resistance post cardiac arrest. Ann Emerg Med 11: 119–126PubMedCrossRefGoogle Scholar
  461. White RP (1979) Multiple origins of cerebral vasospasm. In: Price TR, Nelson E (eds) Cerebro-vascular diseases. Raven Press, New York, pp 307–319Google Scholar
  462. Wieloch T, Siesjö BK (1982) Ischemic brain injury: the importance of calcium, lipolytic activities, and free fatty acids. Pathol Biol (Paris) 30: 269–277Google Scholar
  463. Wiernsperger N, Gyax P, Hofmann A (1984) A calcium antagonist PY 108–068: demonstration of its efficacy in various types of experimental brain ischemia. Stroke 15: 670–683CrossRefGoogle Scholar
  464. Wiill, OW, Walden J, Speckmann EJ, Elger CE (1983) Reduction of penicillin-induced paroxysmal depolarization shifts of rat cerebral cortex by intracellular injection of calcium channel blokker. Neurosci Lett 14: 405–407Google Scholar
  465. Wolff GH (1983) Headache and other head pain. Oxford University Press, New YorkGoogle Scholar
  466. Zahlmann F, Perloff JK, Durant NN, Campion DS (1983) Acute respiratory failure following intravenous verapamil in Duchenne muscular dystrophy. Am Heart J 3: 104–105Google Scholar
  467. Acevedo AG, Smith JK (1988) Adverse reaction to caffeine in ECT. Am J Psychiatry 145: 529–530PubMedGoogle Scholar
  468. Acevedo AMA (1986) Drug evaluations. Saunders, Philadelphia, pp 324–325Google Scholar
  469. Aranda JV, Gorman W, Bergsteinsson H, Gunn T (1977) Efficacy of caffeine in treatment of apnea in the low — birth weight infant. J Pediatr 90: 467–472PubMedCrossRefGoogle Scholar
  470. Arnold LE, Christopher J, Huestis R, Smeltzer DJ (1978) Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction. Am J Psychiatry 35: 463–473Google Scholar
  471. Barone JJ, Roberts HR (1984) Human consumption of caffeine. In: Dews P (ed) Caffeine. Springer, Berlin Heidelberg New York, pp 59–73CrossRefGoogle Scholar
  472. Beach CA, Mays DC, Guiler RC, Jacober CH, Ger-Ber N (1986) Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther 39: 265–270PubMedCrossRefGoogle Scholar
  473. Becker AB, Simons KJ, Gillespie CA, Simons FER (1984) The bronchodilator effects and pharmakokinetics of caffeine in asthma. N Engl J Med 310: 743–746PubMedCrossRefGoogle Scholar
  474. Berkowitz BA, Spector S, Wool W (1971) The interaction of caffeine, theophylline and theobromine with monoaminoxidase inhibitors. Eur J Pharmacol 16: 315PubMedCrossRefGoogle Scholar
  475. Blanchard J, Sawers SJA (1983) The absolute bio-availability of caffeine in man. Eur J Clin Pharmacol 24: 93–98PubMedCrossRefGoogle Scholar
  476. Bonati M, Garattini S (1984) Interspecies comparison of caffeine disposition. In: Dews P (ed) Caffeine. Springer, Berlin Heidelberg New York, pp 48–56CrossRefGoogle Scholar
  477. Boulenger JP, Salem N, Marangos PJ, Uhde TW (1987) Plasma adenosine levels: measurement in humans and relationship to the anxiogenic effects of caffeine. Psychiatr Res 21: 247–255CrossRefGoogle Scholar
  478. Curatolo PW, Robertson D (1983) The health consequences of caffeine. Ann Intern Med 98: 641–653PubMedGoogle Scholar
  479. Debas HT, Cohen MM, Holubitsky IB, Harrison RC (1971) Caffeine-stimulated gastric acid and pepsin secretion: dose-response studies. Scand J Gastroenterol 6: 453–457PubMedCrossRefGoogle Scholar
  480. Deckert J, Gleiter CH (1989) Adenosinergic psychopharmaceuticals. TIPS 10: 99–100PubMedGoogle Scholar
  481. Deckert J, Gleiter CH (1990) Adenosinergic psychopharmaceuticals: just an extra cup of coffee? J Psychopharmacol 4: 183–187PubMedCrossRefGoogle Scholar
  482. Defreitas B, Schwartz G (1979) Effects of caffeine in chronic psychiatric patients. Am J Psychiatry 136: 1337–1338Google Scholar
  483. Dobmeyer DJ, Stine RA, Leier CV, Greenberg R, Schaal SF (1983) The arrhythmogenic effects of caffeine in human beings. N Engl J Med 308: 814–816PubMedCrossRefGoogle Scholar
  484. Eichler O (1976) Atmung und Atemwege. In: Eichler O (Hrsg) Kaffee und Coffein. Springer, Berlin Heidelberg New York, S 171–173Google Scholar
  485. Ellinwood EH, Rockwell WJK (1988) Central nervous system stimulants and anorectic agents. In: Dukes Mng (ed) Meyler’s side effects of drugs. Elsevier, Amsterdam, pp 1–3Google Scholar
  486. Estler CJ (1982) Caffeine. In: Hoffmeister F, Stille G (eds) Handbook of experimental pharma- cology, vol 55/III. Psychotropic agents. Sprin- ger, Berlin Heidelberg New York, pp 369–389CrossRefGoogle Scholar
  487. Estler FDA (1977) Over-the-counter drugs: establishment of monograph for OTC internal analgesic, antipyretic and antirheumatic products. Federal Register 42: 35439–35487Google Scholar
  488. File SE, Bond AJ, Lister RG (1982) Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J Clin Psychopharmacol 2: 102–106PubMedCrossRefGoogle Scholar
  489. Fulgraf G (1976) Niere und Nierenfunktion. In: Eichler O (Hrsg) Kaffee und Coffein. Springer, Berlin Heidelberg New York, S 171–173Google Scholar
  490. Gleiter CH, Deckert J, Nurr DJ (1988) Changes in caffeine seizure threshold after electroconvulsive shock. Psychopharmacology 95: 544–545PubMedGoogle Scholar
  491. Gleiter CH, Deckert J, Nuit DJ, Marangos PJ (1989) Electroconvulsive shock ( ECS) and the adenosine neuromodulatory system. J Neurochem 52: 641–646Google Scholar
  492. Goldstein A, Kaizer S, Warren R (1965) Psychotropic effects of caffeine in man. II. Alertness, psychomotor coordination and mood. J Pharmacol Exp Ther 150: 146–151Google Scholar
  493. Greden JF (1981) Caffeinism and caffeine withdrawal. In: Lowinson JH, Ruiz P (eds) Substance abuse. Williams & Wilkins, Baltimore, pp 274–286Google Scholar
  494. Griffiths RR, Woodson PP (1988) Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology 94: 437–451PubMedCrossRefGoogle Scholar
  495. Haas S, Beckmann H (1983) Psychopharmakotherapie bei (psychotischen) Erregungszuständen. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Springer, Wien New York, S 437–446Google Scholar
  496. Hinkle PE, Coffey CE, Weiner RD, Cress RN, Chri Stison C (1987) Use of caffeine to lengthen seizures in ECT. Am J Psychiatry 144: 1143–1148Google Scholar
  497. Hoeldtke RD, Stephen TC, Hughes JD, Polansky M (1986) Treatment of orthostatic hypotension with dihydroergotamine and caffeine. Ann Intern Med 105: 168–172PubMedGoogle Scholar
  498. Kalow W (1985) Variabilty of caffeine metabolism in humans. Arzneimittelforschung/Drug Res 35: 319–324Google Scholar
  499. Karacan I, Thornby JI, Anch AM, Booth GH, Wil-Liams RL, Salis MA (1976) Dose related sleep disturbances induce by coffee and caffeine. Clin Pharmacol Ther 20: 682–689PubMedGoogle Scholar
  500. Klinz C, Biesold KH (1990) Familiäre paroxysmale dystone Choreoathetose. Nervenarzt 61: 507–509PubMedGoogle Scholar
  501. Laska EM, Sunshine A, Müller F, Elvers WB, Siegel C, Rubin A (1984) Caffeine as an analgesic adjuvant. J Am Med Assoc 251: 1711–1733CrossRefGoogle Scholar
  502. Lee MA, Flegel P, Greden JF, Cameron OG (1988) Anxiogenic effects of caffeine on panic and depressed patients. Am J Psychiatry 145: 632–635PubMedGoogle Scholar
  503. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D (1990) Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28: 35–40PubMedCrossRefGoogle Scholar
  504. Nagesh RV, Murphy KA (1988) Caffeine poisening treated by hemoperfusion. Am J Kidney Dis 12: 316–318PubMedGoogle Scholar
  505. Onrot J, Goldberg MR, Biaggoni I, Hollister AS, Kincaid D, Robertson D (1985) Hemodynamic and humoral effects of caffeine in autonomic failure. N Engl J Med 313: 549–555PubMedCrossRefGoogle Scholar
  506. Onrot J, Shaheen O, Biaggioni I, Goldberg MR, Feely J, Wilkinson GR, Hollister AS, Robertson D (1986) Reduction of liver plasma flow by caffeine and theophylline. Clin Pharmacol Ther 40: 506–510PubMedCrossRefGoogle Scholar
  507. Price KR, Fligner DJ (1990) Treatment of caffeine toxicity with esmolol. Ann Emerg Med 19: 44 46Google Scholar
  508. Rall TW (1990) Drugs used in the treatment of asthma. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 8th ed. Pergamon, New York, pp 618–637Google Scholar
  509. Reynolds JEF (ed) (1989) Martindale, the extra pharmacopeia, 29th ed. The Pharmaceutical Press, London, pp 1522–1524Google Scholar
  510. Robertson D, Frölich JC, Carr RK, Watson JT, Hollifield JW, Shand DG, Oates JA (1978) Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 298: 181–186PubMedCrossRefGoogle Scholar
  511. Schingnitz G, Küfner-Mühl U, Ensinger H, Lehr E (1991) A novel xanthine derivative for treatment of cognitive deficits. Biol Psychiatry 29: 6945Google Scholar
  512. Schnackenberg RC (1973) Caffeine as a substitute for schedule II stimulants in hyperkinetic children. Am J Psychiatry 130: 796–798PubMedGoogle Scholar
  513. Schroder-Rosenstock K (1990) Kaffeekonsum —Ein medizinisches Problem? Münch Med Wochenschr 132: 158–159Google Scholar
  514. Sechzer PH, Abel L (1978) Postspinal anesthesia headache treated with coffeine. Curr Ther Res 24: 307–312Google Scholar
  515. Shapira B, Lerer B, Gilboa B, Drexler H, Kugelmass S, Calev A (1987) Facilitation of ECT by caffeine pretreatment. Am J Psychiatry 144: 1199–1202PubMedGoogle Scholar
  516. Snyder SH (1984) Adenosine as a mediator of the behavioral effects of caffeine. In: DEWS PB (ed) Caffeine. Springer, Berlin Heidelberg New York Tokyo, pp 129–141CrossRefGoogle Scholar
  517. Sobotka TJ (1989) Neurobehavioral effects of prenatal caffeine. Ann NY Acad Sci 562: 327–339PubMedCrossRefGoogle Scholar
  518. Somani SM, Gupta P (1988) Caffeine: a new look at an age-old drug. Int J Clin Pharmacol Toxicol 26: 521–533Google Scholar
  519. Strubelt O (1976) Endokrines System. In: Eichler O (Hrsg) Kaffee und Coffein. Springer, Berlin Heidelberg New York, S 287–296Google Scholar
  520. Strubelt O (1986) Kaffee und Coffein. Dtsch Apotheker Z 38: 2025–2032Google Scholar
  521. Weidner K (1961) Schlaflosigkeit: Versuch mit Kaffee. Selecta 3: 10Google Scholar
  522. Weir RL, Hruska RE (1983) Interaction between methylxanthines and the benzodiazepine receptor. Arch Int Pharmacodyn 254: 42–48Google Scholar
  523. Zenglein R (1975) Behandlung der Migräne. Dtsch Med Wochenschr 100: 557–559PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1992

Authors and Affiliations

  • W. E. Platz
  • J. Böning
  • W. Wesemann
  • N. Weiner
  • A. Hartmann
  • J. Deckert
  • C. H. Gleiter

There are no affiliations available

Personalised recommendations